<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Cardiorenal syndrome</title><meta name="description" content="Cardiorenal syndrome (CRS) refers to the spectrum of disorders in which acute or chronic dysfunction of the heart or kidneys leads to acute or chronic dysfunction of the other.[1] The condition is classified into five subtypes based on the primary organ dysfunction and whether the disease process is acute or chronic. The heart and the kidneys maintain hemodynamic stability and organ perfusion through an intricate network. CRS results from a complex interplay of hemodynamic alterations,..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="CRS, cardio-renal syndrome"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Cardiorenal_syndrome"/><meta property="og:title" content="Cardiorenal syndrome"/><meta property="og:description" content="Cardiorenal syndrome (CRS) refers to the spectrum of disorders in which acute or chronic dysfunction of the heart or kidneys leads to acute or chronic dysfunction of the other.[1] The condition is classified into five subtypes based on the primary organ dysfunction and whether the disease process is acute or chronic. The heart and the kidneys maintain hemodynamic stability and organ perfusion through an intricate network. CRS results from a complex interplay of hemodynamic alterations,..."/><meta property="og:url" content="https://grokipedia.com/page/Cardiorenal_syndrome"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Cardiorenal syndrome"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:13.996Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Cardiorenal syndrome"/><meta name="twitter:description" content="Cardiorenal syndrome (CRS) refers to the spectrum of disorders in which acute or chronic dysfunction of the heart or kidneys leads to acute or chronic dysfunction of the other.[1] The condition is classified into five subtypes based on the primary organ dysfunction and whether the disease process is acute or chronic. The heart and the kidneys maintain hemodynamic stability and organ perfusion through an intricate network. CRS results from a complex interplay of hemodynamic alterations,..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="314a7d77a9afcde3295533630e76111d-f0276817ab494bcb-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=314a7d77a9afcde3295533630e76111d,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.4290948263262171,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cardiorenal-syndrome" class="transition-opacity hover:opacity-100 opacity-50">Cardiorenal syndrome</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cardiorenal-syndrome-1" class="transition-opacity hover:opacity-100 opacity-50">Cardiorenal Syndrome</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#signs-and-symptoms" class="transition-opacity hover:opacity-100 opacity-50">Signs and symptoms</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#risk-factors" class="transition-opacity hover:opacity-100 opacity-50">Risk factors</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical" class="transition-opacity hover:opacity-100 opacity-50">Clinical</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#heart" class="transition-opacity hover:opacity-100 opacity-50">Heart</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#kidney" class="transition-opacity hover:opacity-100 opacity-50">Kidney</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pathophysiology" class="transition-opacity hover:opacity-100 opacity-50">Pathophysiology</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#hemodynamic-factors" class="transition-opacity hover:opacity-100 opacity-50">Hemodynamic factors</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#non-hemodynamic-factors" class="transition-opacity hover:opacity-100 opacity-50">Non-hemodynamic factors</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#diagnosis" class="transition-opacity hover:opacity-100 opacity-50">Diagnosis</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cardiac-biomarkers" class="transition-opacity hover:opacity-100 opacity-50">Cardiac Biomarkers</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#renal-biomarkers" class="transition-opacity hover:opacity-100 opacity-50">Renal Biomarkers</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#non-invasive-imaging" class="transition-opacity hover:opacity-100 opacity-50">Non-Invasive Imaging</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#classification" class="transition-opacity hover:opacity-100 opacity-50">Classification</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#type-1-acute-cardio-renal-syndrome" class="transition-opacity hover:opacity-100 opacity-50">Type 1: Acute cardio-renal syndrome</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#type-2-chronic-cardio-renal-syndrome" class="transition-opacity hover:opacity-100 opacity-50">Type 2: Chronic cardio-renal syndrome</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#type-3-acute-reno-cardiac-syndrome" class="transition-opacity hover:opacity-100 opacity-50">Type 3: Acute reno-cardiac syndrome</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#type-4-chronic-reno-cardiac-syndrome" class="transition-opacity hover:opacity-100 opacity-50">Type 4: Chronic reno-cardiac syndrome</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#type-5-secondary-cardiorenal-syndrome" class="transition-opacity hover:opacity-100 opacity-50">Type 5: Secondary cardiorenal syndrome</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#management" class="transition-opacity hover:opacity-100 opacity-50">Management</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#diuretics" class="transition-opacity hover:opacity-100 opacity-50">Diuretics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#ace-inhibitors-angiotensin-ii-receptor-blockers-arb" class="transition-opacity hover:opacity-100 opacity-50">ACE Inhibitors, Angiotensin II receptor blockers (ARB)</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#angiotensin-receptor-neprilysin-inhibitors-arni" class="transition-opacity hover:opacity-100 opacity-50">Angiotensin receptor neprilysin inhibitors (ARNI)</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#sodium-glucose-cotransporter-2-sglt2-inhibitors" class="transition-opacity hover:opacity-100 opacity-50">Sodium-glucose cotransporter 2 (SGLT2) Inhibitors</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#mineralocorticoid-receptor-antagonists-mra" class="transition-opacity hover:opacity-100 opacity-50">Mineralocorticoid Receptor Antagonists (MRA)</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#beta-adrenergic-blockers" class="transition-opacity hover:opacity-100 opacity-50">Beta-adrenergic blockers</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#ultrafiltration" class="transition-opacity hover:opacity-100 opacity-50">Ultrafiltration</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#inotropes" class="transition-opacity hover:opacity-100 opacity-50">Inotropes</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cardiac-resynchronization-therapy-crt" class="transition-opacity hover:opacity-100 opacity-50">Cardiac Resynchronization Therapy (CRT)</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#epidemiology" class="transition-opacity hover:opacity-100 opacity-50">Epidemiology</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="cardiorenal-syndrome" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Cardiorenal syndrome<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Cardiorenal syndrome</strong> (<strong>CRS</strong>) refers to the spectrum of disorders in which acute or chronic dysfunction of the heart or kidneys leads to acute or chronic dysfunction of the other.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The condition is classified into five subtypes based on the primary organ dysfunction and whether the disease process is acute or chronic. The heart and the kidneys maintain hemodynamic stability and organ perfusion through an intricate network. CRS results from a complex interplay of hemodynamic alterations, neurohormonal activation, inflammatory mediators, and endothelial dysfunction, all contributing to progressive organ injury.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Cardiorenal syndrome is commonly associated with conditions such as heart failure, chronic kidney disease (CKD), acute kidney injury (AKI), and systemic hypertension.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Management of CRS primarily focuses on addressing the underlying cause while mitigating the complications associated with the syndrome. Since volume overload is a predominant feature in most patients, treatment typically involves fluid removal, primarily through loop diuretics, with thiazides as adjuncts for diuretic resistant cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Ultrafiltration is reserved for refractory cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Depending on the case, additional therapies such as ACE inhibitors, angiotensin II receptor blockers, angiotensin receptor neprilysin inhibitors (ARNI), sodium-glucose cotransporter 2 (SGLT2) inhibitors, mineralocorticoid receptor antagonists, and inotropes may be utilized.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Despite available treatments, CRS remains associated with high morbidity and mortality.</span>
<h1 id="cardiorenal-syndrome-1" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Cardiorenal Syndrome<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="signs-and-symptoms" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Signs and symptoms<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Cardiorenal syndrome (CRS) encompasses a spectrum of disorders in which acute or chronic dysfunction in the heart or kidneys leads to dysfunction in the other organ. Therefore, the clinical signs and symptoms are consistent with congestive heart failure and chronic kidney disease. The clinical presentation of most patients typically involves fluid overload and worsening renal function. Patients may exhibit features of both acute and chronic forms, with acute presentations often including pulmonary or systemic congestion and acute kidney injury.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> In chronic cases, symptoms develop more gradually, including progressive fatigue, exercise intolerance, nocturia, and uremic manifestations such as nausea, anorexia, and pruritus.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Symptoms of peripheral edema and shortness of breath are common both in patients with CHF and CKD or a combination thereof. Patients will frequently exhibit signs of acute decompensated heart failure, such as volume overload characterized by peripheral edema, pulmonary congestion, jugular venous distension, and shortness of breath.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Prolonged effects of heart failure, such as fatigue and exercise intolerance, may also be present. Additional signs can include ascites, an S3 gallop, bibasilar rales, and in cases of low-output states, hypotension and cool extremities.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Symptoms of cardiorenal syndrome often present with classic indicators of renal dysfunction. Increased serum levels of creatinine and BUN, as well as reduced urine production (oliguria), may indicate worsening renal function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> In advanced cases, electrolyte imbalances or uremia may contribute to confusion or altered mentation.</span>
<h2 id="risk-factors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Risk factors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The primary risk factors for the development of cardiorenal syndrome are pre-existing cardiac or renal disease. The following risk factors have been associated with increased incidence of CRS.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h3 id="clinical" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Clinical<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Older age</li>
<li class="text-[1em]">Comorbid conditions (diabetes mellitus, uncontrolled hypertension, anemia)</li>
<li class="text-[1em]">Drugs (anti-inflammatory agents, diuretics, ACE inhibitors, ARBs)</li>
</ul>
<h3 id="heart" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Heart<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">History of heart failure with impaired left ventricular ejection fraction</li>
<li class="text-[1em]">Prior myocardial infarction</li>
<li class="text-[1em]">Elevated New York Heart Association (NYHA) functional class</li>
<li class="text-[1em]">Elevated cardiac troponins</li>
</ul>
<h3 id="kidney" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Kidney<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Chronic kidney disease (reduced eGFR, elevated BUN, creatinine, or cystatin)</li>
</ul>
<h2 id="pathophysiology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Pathophysiology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Cardiorenal syndrome (CRS) pathophysiology involves a complex bidirectional interaction between the heart and kidneys. The underlying mechanisms are broadly categorized into hemodynamic and non-hemodynamic factors. Hemodynamic factors primarily include changes in blood flow, such as reduced cardiac output and elevated <span class="inline text-[1em] leading-7">central venous</span> or intra-abdominal pressures. Non-hemodynamic factors include <span class="inline text-[1em] leading-7">neurohormonal</span> activation, <span class="inline text-[1em] leading-7">oxidative stress</span>, and <span class="inline text-[1em] leading-7">systemic inflammation</span>. These mechanisms often act synergistically, contributing to the progressive dysfunction of both organs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<h3 id="hemodynamic-factors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Hemodynamic factors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Reduced <span class="inline text-[1em] leading-7">cardiac output</span>, commonly due to heart failure or other cardiovascular conditions, leads to decreased renal perfusion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> Historically, this reduction in perfusion was considered the primary driver of kidney dysfunction in heart failure. However, recent studies suggest that <span class="inline text-[1em] leading-7">venous congestion</span> may play an even more critical role. Heart failure increases central venous and intra-abdominal pressures, which are important regulators of renal blood flow.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> Elevated venous pressures reduce the net glomerular filtration pressure, promoting renal injury.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> These changes contribute to worsening volume overload and further deterioration of cardiac and renal function.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The <span class="inline text-[1em] leading-7">renin-angiotensin-aldosterone system</span> (RAAS) is activated in response to reduced renal perfusion. Although RAAS normally helps maintain blood pressure and organ perfusion, chronic over-activation leads to inappropriate sodium and water retention. This exacerbates volume overload and perpetuates a cycle of worsening heart and kidney function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<h3 id="non-hemodynamic-factors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Non-hemodynamic factors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In addition to hemodynamic changes, several non-hemodynamic mechanisms contribute to the progression of CRS. These include neurohormonal activation, oxidative stress, and systemic inflammation, all of which are associated with structural and functional deterioration in both the heart and kidneys.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Neurohormonal systems, primarily the RAAS and sympathetic nervous system (SNS), are activated in response to reduced renal perfusion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> In heart failure, these systems become over-activated, causing peripheral vasoconstriction and extracellular fluid retention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Beyond hemodynamic effects, RAAS and SNS activation stimulate oxidative and inflammatory pathways and contribute to cardiac remodeling and progressive dysfunction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ccabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Oxidative stress and inflammation also play critical roles. Elevated levels of <span class="inline text-[1em] leading-7">reactive oxygen species</span> (ROS), <span class="inline text-[1em] leading-7">endothelin</span>, and <span class="inline text-[1em] leading-7">arginine vasopressin</span> contribute to endothelial dysfunction, myocardial hypertrophy, and fibrosis, as well as to renal tubular injury and glomerular dysfunction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> An imbalance between <span class="inline text-[1em] leading-7">nitric oxide</span> and ROS exacerbates endothelial dysfunction and impairs organ perfusion. There is a close interaction within these cardio-renal connectors as well as between these factors and the hemodynamic factors which makes the study of CRS pathophysiology complicated.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ocqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<h1 id="diagnosis" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Diagnosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">Diagnosing cardiorenal syndrome (CRS) is challenging due to the complex and interconnected nature of cardiac and renal dysfunction. It is critical to diagnose CRS at an early stage in order to achieve optimal therapeutic efficacy. There is no specific test to diagnose cardiorenal syndrome. Instead, diagnosis relies on clinical evaluation, laboratory data, and imaging, often in the context of known heart failure, kidney disease, or both.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> The diagnosis of heart failure requires the presence of clinical signs and symptoms supported by evidence of a structural or functional cardiac abnormality. This diagnostic requirement for cardiorenal syndrome includes similar evidence for both the heart and kidneys.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h2 id="cardiac-biomarkers" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Cardiac Biomarkers<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Cardiac biomarkers can help to identify cardiac dysfunction in the evaluation for Cardiorenal syndrome. Brain natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are peptides elevated in the presence of cardiac stress and volume overload.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Cardiac troponin is a biomarker that can be useful to indicate ongoing myocardial damage and stress. The use of BNP, NT-proBNP, and troponin can be confounded by decreased renal clearance in patients with impaired renal function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Despite the limitations, these biomarkers can help to identify cardiac dysfunction crucial to the diagnosis of CRS. Though less frequently used in clinical practice, Galectin-3 and ST2 (suppressor of tumorigenicity 2), markers of fibrosis and myocardial stress, can add prognostic value.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ceqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h2 id="renal-biomarkers" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Renal Biomarkers<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Unlike markers of heart damage or stress such as troponin, creatine kinase, natriuretic peptides, reliable markers for acute kidney injury are lacking. Recently, research has found several biomarkers that can be used for early detection of acute kidney injury before serious loss of organ function may occur. Several of these biomarkers include neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-B-D-glucosaminidase (NAG), Cystatin C, kidney injury molecule-1 (KIM-1), and tissue inhibitor of metalloproteinases-2/interleukin-6 finger-binding protein 7 (TIMP-2/IGFBP7) which have been shown to be involved in tubular damage.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Other biomarkers that have been shown to be useful include BNP, IL-18, and fatty acid binding protein (FABP).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_afqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> However, there is great variability in the measurement of these biomarkers and their use in diagnosing CRS must be assessed.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_efqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<h2 id="non-invasive-imaging" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Non-Invasive Imaging<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The diagnosis of Cardiorenal syndrome utilizes imaging to provide key insights into structural and functional changes in the heart and kidneys. Echocardiography is the primary tool to assess heart function and can provide data on heart chamber performance, valvular abnormalities, and estimates of filling pressures. Lung ultrasound is a commonly used bedside tool to identify pulmonary edema.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Imaging of the kidneys is commonly performed using ultrasound to assess size, structural changes, and perfusion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h1 id="classification" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Classification<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">Ronco et al. first proposed a five-part classification system for CRS in 2008 which was also accepted at ADQI consensus conference in 2010.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> These include:</span>









































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Type</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Inciting event</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Secondary disturbance</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Example</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Type 1</strong><span class="text-[1em] leading-7"> (</span><em>acute CRS</em><span class="text-[1em] leading-7">)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Abrupt worsening of heart function</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">kidney injury</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">acute </span><span class="inline text-[1em] leading-7">cardiogenic shock</span><span class="text-[1em] leading-7"> or </span><span class="inline text-[1em] leading-7">acute decompensation of chronic heart failure</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Type 2</strong><span class="text-[1em] leading-7"> (</span><em>chronic CRS</em><span class="text-[1em] leading-7">)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Chronic abnormalities in heart function</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">progressive </span><span class="inline text-[1em] leading-7">chronic kidney disease</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">chronic heart failure</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Type 3</strong><span class="text-[1em] leading-7"> (</span><em>acute renocardiac syndrome</em><span class="text-[1em] leading-7">)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Abrupt worsening of kidney function</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">acute cardiac disorder (e.g. heart failure, </span><span class="inline text-[1em] leading-7">abnormal heart rhythm</span><span class="text-[1em] leading-7">, or pulmonary edema)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">acute kidney failure</span><span class="text-[1em] leading-7"> or </span><span class="inline text-[1em] leading-7">glomerulonephritis</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Type 4</strong><span class="text-[1em] leading-7"> (</span><em>chronic renocardiac syndrome</em><span class="text-[1em] leading-7">)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Chronic kidney disease</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">decreased cardiac function, cardiac hypertrophy and/or increased risk of adverse cardiovascular events</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">chronic glomerular disease</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Type 5</strong><span class="text-[1em] leading-7"> (</span><em>secondary CRS</em><span class="text-[1em] leading-7">)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Systemic condition</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">both heart and kidney dysfunction</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">diabetes mellitus, </span><span class="inline text-[1em] leading-7">sepsis</span><span class="text-[1em] leading-7">, lupus</span></td></tr></tbody></table></div>
<h3 id="type-1-acute-cardio-renal-syndrome" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Type 1: Acute cardio-renal syndrome<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Acute cardiorenal syndrome occurs in patients who experience an abrupt decrease in cardiac function, causing an acute kidney injury and/or dysfunction. The sudden reduction in kidney function is frequently caused by <span class="inline text-[1em] leading-7">acute decompensated heart failure</span>, <span class="inline text-[1em] leading-7">acute coronary syndrome</span>, <span class="inline text-[1em] leading-7">cardiogenic shock</span>, and/or low flow syndrome following cardiac surgery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> The extent of renal injury can vary, often causing <span class="inline text-[1em] leading-7">acute kidney injury (AKI)</span>, but it can also result in acute renal failure. Type 1 CRS carries the risk of advancing to more severe stages of chronic kidney disease and <span class="inline text-[1em] leading-7">end-stage renal disease (ESRD)</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_sjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<h3 id="type-2-chronic-cardio-renal-syndrome" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Type 2: Chronic cardio-renal syndrome<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Type 2 CRS refers to the specific situation in which chronic heart dysfunction results in progressive kidney dysfunction. Cardiac conditions such as heart failure with reduced or preserved ejection fraction, atrial fibrillation, ischemic cardiomyopathy, and congenital heart disease can result in adaptive changes in renal perfusion and neurohormonal activation over time.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> These conditions cause a time-dependent and progressive decline in renal function.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The distinction between CRS type 2 and CRS type 4 is based on the assumption that, also in advanced and chronic disease, two different pathophysiological mechanisms can be distinguished, whereas both CKD and HF often develop due to a common pathophysiological background, most notably <span class="inline text-[1em] leading-7">hypertension</span> and <span class="inline text-[1em] leading-7">diabetes mellitus</span>. Furthermore, the feasibility of the distinction between CRS type 2 and 4 in terms of diagnosis can be questioned.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ckqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup></span>
<h3 id="type-3-acute-reno-cardiac-syndrome" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Type 3: Acute reno-cardiac syndrome<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Type 3 CRS involves a abrupt decrease in renal function resulting in an acute cardiac disorder. An example of type 3 CRS would be the development of <span class="inline text-[1em] leading-7">acute heart failure</span>, <span class="inline text-[1em] leading-7">acute coronary syndrome</span> or <span class="inline text-[1em] leading-7">arrhythmia</span> following the onset of an AKI, or intrinsic kidney disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_glqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Drug-induced renal disease, <span class="inline text-[1em] leading-7">rhabdomyolysis</span>, and <span class="inline text-[1em] leading-7">acute nephritic syndromes</span> have been associated with Type 3 CRS.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_slqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<h3 id="type-4-chronic-reno-cardiac-syndrome" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Type 4: Chronic reno-cardiac syndrome<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Type 4 cardiorenal syndrome is the development of chronic heart dysfunction as a result of chronic kidney disease. Many studies have found increased rates of cardiovascular disease in patients with CKD, that occur in a dose-dependent relationship, with the greatest reductions in GFR resulting in the greatest risk for CVD development.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> The data from scientific literature indicates that CKD increases the risk for developing heart disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h3 id="type-5-secondary-cardiorenal-syndrome" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Type 5: Secondary cardiorenal syndrome<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">This subtype of CRS refers to a separate condition resulting in simultaneous cardiac and renal systems dysfunction. These cases often involve a systemic illness such as <span class="inline text-[1em] leading-7">sepsis</span>, multiple traumas, <span class="inline text-[1em] leading-7">amyloidosis</span>, <span class="inline text-[1em] leading-7">sarcoidosis</span>, <span class="inline text-[1em] leading-7">diabetes mellitus</span>, <span class="inline text-[1em] leading-7">hepatitis b</span>, <span class="inline text-[1em] leading-7">hepatitis c</span>, <span class="inline text-[1em] leading-7">systemic lupus erythematosus (SLE)</span>, and significant burns, causing an abrupt decrease in both cardiac and renal function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Type 5 CRS can also be the result of the administration of <span class="inline text-[1em] leading-7">chemotherapy medications</span> and the use of illicit substances such as <span class="inline text-[1em] leading-7">heroin</span> and <span class="inline text-[1em] leading-7">cocaine</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1gnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1inqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Braam et al. argue that classifying the CRS based on the order in which the organs are affected and the timeframe (acute vs chronic) is too simplistic and without a mechanistic classification it is difficult to study CRS.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> They view the cardiorenal syndrome in a more holistic, integrative manner.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aoabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> They defined the cardiorenal syndrome as a pathophysiological condition in which combined heart and kidney dysfunction amplifies progression of failure of the individual organ, by inducing similar pathophysiological mechanisms. Therefore, regardless of which organ fails first, the same neurohormonal systems are activated causing accelerated cardiovascular disease, and progression of damage and failure of both organs. These systems are broken down into two broad categories of &quot;hemodynamic factors&quot; and non-hemodynamic factors or &quot;cardiorenal connectors&quot;.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eoabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<h1 id="management" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Management<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">Medical management of patients with CRS is often challenging as the treatment of one organ system may adversely affect the other. Many of the medications used to treat heart failure may worsen kidney function. Chronic kidney disease has been shown to have an adverse effect on morbidity and mortality in patients with heart failure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> Historically, many of the most impactful clinical trials regarding heart failure management excluded patients with significant renal impairment, limiting early understanding of treatment in cardiorenal syndrome; however, recent trials have included CKD patients, enhancing evidence-based management.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_apabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> The management of cardiorenal syndrome will vary depending on the subtype, as well as individual patient considerations.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Patients with kidney failure are less likely to get all guideline-based therapies. Patients with moderate CKD often received similar guideline-based care to those with normal kidney function, though with lower use of ACE inhibitors/ARBs and blood pressure control; severe CKD patients had more disparities. This highlights opportunities for healthcare providers to improve outcomes in CRS patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<h3 id="diuretics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Diuretics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Diuretics play a crucial role in managing fluid overload in patients with acute heart failure, with or without CRS. Although not supported by data from large clinical trials like other heart failure treatments, the clinical best practices regarding diuretics remain uncertain. Diuretics are widely considered a standard of care to reduce volume overload caused by acute heart failure based on expert opinion alone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Guidelines recommend using diuretics cautiously by using minimal required dosing and close monitoring in patients with kidney disease, as they may potentially cause dehydration and worsening renal function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> Loop diuretics are the primary agents used in heart failure. Diuretic resistance is frequently a challenge for physicians to overcome which they may tackle by changing the dosage, frequency, or adding a second drug.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<h3 id="ace-inhibitors-angiotensin-ii-receptor-blockers-arb" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">ACE Inhibitors, Angiotensin II receptor blockers (ARB)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The use of ACE inhibitors has long-term protective effects on kidney and heart tissue. Angiotensin inhibition with an ACE inhibitor or angiotensin II receptor blocker (ARB) is a standard part of treatment for heart failure. The use of ACE inhibitors and ARBs in heart failure has been shown to improve survival and reduce kidney dysfunction. However, they should be used with caution in patients with CRS and kidney failure. Although patients with kidney failure may experience slight deterioration of kidney function in the short term, the use of ACE inhibitors is shown to have prognostic benefit over the long term.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Studies have suggested that the use of ACEI alongside statins might be an effective regimen to prevent a substantial number of CRS cases in high-risk patients and improve survival and quality of life in these people. There are data suggesting combined use of statin and an ACEI improves clinical outcome more than a statin alone and considerably more than ACE inhibitor alone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></span>
<h3 id="angiotensin-receptor-neprilysin-inhibitors-arni" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Angiotensin receptor neprilysin inhibitors (ARNI)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">A class of drugs for the treatment of chronic heart failure, angiotensin receptor neprilysin inhibitors (ARNI), has emerged as an alternative to ACE inhibitors and ARBs. This drug class has the effects of an ARB, blocking the effects of angiotensin II, combined with the inhibition of the enzyme neprilysin, which prevents the breakdown of natriuretic peptides.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> Clinical studies have shown the clinical benefits of ARNIs in patients with heart failure and chronic kidney disease, supporting their use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> ARNIs are recommended in guidelines for heart failure management applicable to CRS, with established use in HFrEF and emerging evidence in HFpEF with CKD.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_csqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup></span>
<h3 id="sodium-glucose-cotransporter-2-sglt2-inhibitors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Sodium-glucose cotransporter 2 (SGLT2) Inhibitors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Sodium-glucose cotransporter 2 (SGLT2) inhibitors are medications commonly used in regimens for treating heart failure and preserving renal function. SGLT2 inhibitors function to block glucose reabsorption in the kidney. These agents have demonstrated cardiovascular and renal protective benefits, such as reducing volume overload and preventing kidney damage caused by inflammation and oxidative stress.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<h3 id="mineralocorticoid-receptor-antagonists-mra" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Mineralocorticoid Receptor Antagonists (MRA)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Treatment with an ACE inhibitor or ARB may not sufficiently suppress the RAAS system in the long term. Mineralocorticoid receptor antagonists may be added to the regimen to provide additional RAAS suppression, resulting in more significant long-term cardiorenal benefits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Non-steroidal MRAs like finerenone provide additional cardiorenal benefits in CKD with type 2 diabetes and HF, reducing progression to ESRD and CV events.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_auqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup></span>
<h3 id="beta-adrenergic-blockers" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Beta-adrenergic blockers<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Beta-blockers are commonly used in guideline-directed heart failure medication regimens and may also be used in the treatment of cardiorenal syndrome. By blocking the effects of epinephrine, beta-blockers reduce blood pressure and significantly improve mortality and hospitalization rates in patients with heart failure and chronic kidney disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<h3 id="ultrafiltration" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Ultrafiltration<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Ultrafiltration involves the removal of fluid from the venous system via filtration, in a process similar to dialysis. Ultrafiltration is generally reserved for patients in acute decompensated heart failure that have volume overload resistant to diuretics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Many case reports have shown improved kidney function with ultrafiltration, however the clinical value has yet to be established.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h3 id="inotropes" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Inotropes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Inotropes are a class of drugs that enhance the contractile force produced by the heart and the overall cardiac output.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> Due to their mechanism, they have the potential to treat cardiorenal syndrome by improving heart function and reducing venous congestion. However, the efficacy of inotropes as a long-term therapy has yet to be proven. They may be used in patients with cardiorenal syndrome in the instance of cardiogenic shock.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h3 id="cardiac-resynchronization-therapy-crt" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Cardiac Resynchronization Therapy (CRT)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">CRT, a form of cardiac pacing, helps to improve heart function by electrically activating the ventricles to synchronize their contractions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> CRT has been shown to improve renal response in patients with chronic kidney disease and congestive heart failure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_92qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup></span>
<h2 id="epidemiology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Epidemiology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Kidney failure is very common in patients with congestive heart failure. AKI complicates approximately one-third of heart failure admissions, which remains the leading cause of hospitalization in the United States among adults over 65 years old as of 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_73qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> This not only drives hospitalizations but also increases the likelihood of ICU admission.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> These complications result in longer hospital stays, higher mortality, and greater risk of readmission. Inpatient mortality is substantially higher in patients with severe renal dysfunction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> Increased hospital and ICU utilization also raises healthcare costs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> Patients with heart failure and renal impairment face significant economic burden from prolonged care. In heart failure patients, renal impairment is associated with more severe symptoms; for example, chronic kidney disease is present in approximately 40-60% of those with heart failure, contributing to cardiorenal syndrome.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_n3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Similarly, kidney failure adversely affects cardiovascular function. As of 2024, 51.5% of deaths among patients with end-stage kidney disease (with known cause) are attributable to cardiovascular disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_r3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. (March 2010). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838681" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative&quot;</a>. <em>European Heart Journal</em>. <strong>31</strong> (6): 703â€“711. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Feurheartj%2Fehp507" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/eurheartj/ehp507</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838681" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2838681</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20037146" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20037146</a>.</span></div></li><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Braam B, Joles JA, Danishwar AH, Gaillard CA (January 2014). &quot;Cardiorenal syndrome--current understanding and future perspectives&quot;. <em>Nature Reviews. Nephrology</em>. <strong>10</strong> (1): 48â€“55. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fnrneph.2013.250" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/nrneph.2013.250</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24247284" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24247284</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:7556399" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7556399</a>.</span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ajibowo, Abimbola O.; Okobi, Okelue E.; Emore, Erhieyovbe; Soladoye, Elizabeth; Sike, Cherechi G.; Odoma, Victor A.; Bakare, Ibrahim O.; Kolawole, Olasunkanmi A.; Afolayan, Adebola; Okobi, Emeka; Chukwu, Chinyereadaeze; Ajibowo, Abimbola O.; Okobi, Okelue E.; Emore, Erhieyovbe; Soladoye, Elizabeth (2023-07-01). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389294" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cardiorenal Syndrome: A Literature Review&quot;</a>. <em>Cureus</em>. <strong>15</strong> (7): e41252. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.7759%2Fcureus.41252" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.7759/cureus.41252</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/2168-8184" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2168-8184</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389294" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10389294</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/37529809" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">37529809</a>.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Thind, Guramrinder S.; Loehrke, Mark; Wilt, Jeffrey L. (March 2018). &quot;Acute cardiorenal syndrome: Mechanisms and clinical implications&quot;. <em>Cleveland Clinic Journal of Medicine</em>. <strong>85</strong> (3): 231â€“239. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.3949%2Fccjm.85a.17019" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.3949/ccjm.85a.17019</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1939-2869" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1939-2869</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29522391" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29522391</a>.</span></div></li><li id="5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Rangaswami, Janani; Bhalla, Vivek; Blair, John E.A.; Chang, Tara I.; Costa, Salvatore; Lentine, Krista L.; Lerma, Edgar V.; Mezue, Kenechukwu; Molitch, Mark; Mullens, Wilfried; Ronco, Claudio; Tang, W.H. Wilson; McCullough, Peter A.; On behalf of the American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology (2019-04-16). <a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000000664" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association&quot;</a>. <em>Circulation</em>. <strong>139</strong> (16): e840 â€“ e878. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1161%2FCIR.0000000000000664" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1161/CIR.0000000000000664</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/30852913" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">30852913</a>.</span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Verma, Deepak; Firoz, Amena; Garlapati, Sameer Krishna Prasad; Sai Charaan Reddy Sathi, Thanmay; Haris, Muhammad; Dhungana, Bibek; Ray, Barun; Shah, Gunjan; Kc, Bibek; Paudel, Palak (2021-08-17). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448169" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management&quot;</a>. <em>Cureus</em>. <strong>13</strong> (8): e17240. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.7759%2Fcureus.17240" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.7759/cureus.17240</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/2168-8184" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2168-8184</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448169" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8448169</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/34540466" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">34540466</a>.</span></div></li><li id="25" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Nicolas, Diala; Kerndt, Connor C.; Patel, Preeti; Reed, Mirembe (2025), <a href="https://www.ncbi.nlm.nih.gov/books/NBK507904/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Sacubitril-Valsartan&quot;</a>, <em>StatPearls</em> , Treasure Island (FL): StatPearls Publishing, <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29939681" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29939681</a>, retrieved 2025-03-25</span></div></li><li id="26" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Margonato, Davide; Galati, Giuseppe; Mazzetti, Simone; Cannistraci, Rosa; Perseghin, Gianluca; Margonato, Alberto; Mortara, Andrea (2021-03-01). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895775" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors&quot;</a>. <em>Heart Failure Reviews</em>. <strong>26</strong> (2): 337â€“345. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1007%2Fs10741-020-10024-2" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1007/s10741-020-10024-2</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1573-7322" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1573-7322</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895775" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7895775</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/32901315" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">32901315</a>.</span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ronco, Claudio; Cicoira, Mariantonietta; McCullough, Peter A. (2012-09-18). <a href="https://www.sciencedirect.com/science/article/pii/S0735109712019559" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cardiorenal Syndrome Type 1: Pathophysiological Crosstalk Leading to Combined Heart and Kidney Dysfunction in the Setting of Acutely Decompensated Heart Failure&quot;</a>. <em>Journal of the American College of Cardiology</em>. <strong>60</strong> (12): 1031â€“1042. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.jacc.2012.01.077" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.jacc.2012.01.077</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0735-1097" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0735-1097</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22840531" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22840531</a>.</span></div></li><li id="8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Wang, Jin; Zhang, Weiguang; Wu, Lingling; Mei, Yan; Cui, Shaoyuan; Feng, Zhe; Chen, Xiangmei (2020-06-19). <a href="https://www.aging-us.com/article/103354/text" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;New insights into the pathophysiological mechanisms underlying cardiorenal syndrome&quot;</a>. <em>Aging</em>. <strong>12</strong> (12): 12422â€“12431. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.18632%2Faging.103354" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.18632/aging.103354</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1945-4589" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1945-4589</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343447" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7343447</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/32561688" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">32561688</a>.</span></div></li><li id="9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Viswanathan G, Gilbert S (October 2010). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989717" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The cardiorenal syndrome: making the connection&quot;</a>. <em>International Journal of Nephrology</em>. <strong>2011</strong> : 283137. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.4061%2F2011%2F283137" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.4061/2011/283137</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989717" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2989717</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21151533" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21151533</a>.</span></div></li><li id="10" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kousa, Omar; Mullane, Ryan; Aboeata, Ahmed (2025), <a href="https://www.ncbi.nlm.nih.gov/books/NBK542305/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cardiorenal Syndrome&quot;</a>, <em>StatPearls</em> , Treasure Island (FL): StatPearls Publishing, <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/31194445" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">31194445</a>, retrieved 2025-03-22</span></div></li><li id="12" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ceravolo, Giorgia; Macchia, Tommaso La; Cuppari, Caterina; Dipasquale, Valeria; Gambadauro, Antonella; Casto, Celeste; Ceravolo, Maria Domenica; Cutrupi, Maricia; CalabrÃ², Maria Pia; Borgia, Paola; Piccolo, Gianluca; Mancuso, Alessio; Albiero, Remo; Chimenz, Roberto (2021-06-22). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305733" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Update on the Classification and Pathophysiological Mechanisms of Pediatric Cardiorenal Syndromes&quot;</a>. <em>Children</em>. <strong>8</strong> (7): 528. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.3390%2Fchildren8070528" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.3390/children8070528</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/2227-9067" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2227-9067</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305733" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8305733</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/34206173" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">34206173</a>.</span></div></li><li id="13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Raina, Rupesh; Nair, Nikhil; Chakraborty, Ronith; Nemer, Lena; Dasgupta, Rahul; Varian, Kenneth (2020). <a href="https://www.cardiologyres.org/index.php/Cardiologyres/article/view/955/1029" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;An Update on the Pathophysiology and Treatment of Cardiorenal Syndrome&quot;</a>. <em>Cardiology Research</em>. <strong>11</strong> (2): 76â€“88. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.14740%2Fcr955" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.14740/cr955</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1923-2829" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1923-2829</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092771" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7092771</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/32256914" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">32256914</a>.</span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pokhrel N, Maharjan N, Dhakal B, Arora RR (2008). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663478" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cardiorenal syndrome: A literature review&quot;</a>. <em>Experimental and Clinical Cardiology</em>. <strong>13</strong> (4): 165â€“170. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663478" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2663478</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/19343160" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">19343160</a>.</span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Expert Group on Biomarkers (May 2015). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495448" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Biomarkers in Cardiology - Part 2: In Coronary Heart Disease, Valve Disease and Special Situations&quot;</a>. <em>Arquivos Brasileiros de Cardiologia</em>. <strong>104</strong> (5): 337â€“346. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.5935%2Fabc.20150061" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.5935/abc.20150061</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495448" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4495448</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/26083777" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26083777</a>.</span></div></li><li id="16" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">McCullough, Peter A. (2011). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995900" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cardiorenal Syndromes: Pathophysiology to Prevention&quot;</a>. <em>International Journal of Nephrology</em>. <strong>2011</strong> : 1â€“10. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.4061%2F2011%2F762590" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.4061/2011/762590</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/2090-214X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2090-214X</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995900" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2995900</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21151537" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21151537</a>.</span></div></li><li id="17" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Di Lullo L, Bellasi A, Barbera V, Russo D, Russo L, Di Iorio B, et al. (2017-03-01). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415026" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate&quot;</a>. <em>Indian Heart Journal</em>. <strong>69</strong> (2): 255â€“265. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.ihj.2017.01.005" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.ihj.2017.01.005</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415026" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">5415026</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/28460776" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28460776</a>.</span></div></li><li id="18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B (January 2005). <a href="https://doi.org/10.1093%2Feurheartj%2Fehi020" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The severe cardiorenal syndrome: &#x27;Guyton revisited&#x27;&quot;</a>. <em>European Heart Journal</em>. <strong>26</strong> (1): 11â€“17. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Feurheartj%2Fehi020" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/eurheartj/ehi020</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15615794" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15615794</a>.</span></div></li><li id="19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">McDonagh, Theresa A; Metra, Marco; Adamo, Marianna; Gardner, Roy S; Baumbach, Andreas; BÃ¶hm, Michael; Burri, Haran; Butler, Javed; ÄŒelutkienÄ—, Jelena; Chioncel, Ovidiu; Cleland, John G F; Coats, Andrew J S; Crespo-Leiro, Maria G; Farmakis, Dimitrios; Gilard, Martine (2021-12-21). <a href="https://academic.oup.com/eurheartj/article/42/48/4901/6397185" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC&quot;</a>. <em>European Heart Journal</em>. <strong>42</strong> (48): 4901. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Feurheartj%2Fehab670" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/eurheartj/ehab670</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0195-668X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0195-668X</a>.</span></div></li><li id="https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063</a></span></div></li><li id="20" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Damman, Kevin; Tang, W. H. Wilson; Felker, G. Michael; Lassus, Johan; Zannad, Faiez; Krum, Henry; McMurray, John J. V. (2014-03-11). <a href="https://linkinghub.elsevier.com/retrieve/pii/S0735109713064255" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data&quot;</a>. <em>Journal of the American College of Cardiology</em>. <strong>63</strong> (9): 853â€“871. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.jacc.2013.11.031" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.jacc.2013.11.031</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0735-1097" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0735-1097</a>.</span></div></li><li id="21" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Gnanaraj J, Radhakrishnan J (2016-08-31). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007748" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cardio-renal syndrome&quot;</a>. <em>F1000Research</em>. <strong>5</strong> : F1000 Faculty Revâ€“2123. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.12688%2Ff1000research.8004.1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.12688/f1000research.8004.1</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007748" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">5007748</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/27635229" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">27635229</a>.</span></div></li><li id="22" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Patel UD, Hernandez AF, Liang L, Peterson ED, LaBresh KA, Yancy CW, et al. (October 2008). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2604122" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study&quot;</a>. <em>American Heart Journal</em>. <strong>156</strong> (4): 674â€“681. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.ahj.2008.05.028" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.ahj.2008.05.028</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2604122" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2604122</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/18946892" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">18946892</a>.</span></div></li><li id="23" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Shah BN, Greaves K (December 2010). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021842" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The cardiorenal syndrome: a review&quot;</a>. <em>International Journal of Nephrology</em>. <strong>2011</strong> : 920195. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.4061%2F2011%2F920195" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.4061/2011/920195</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021842" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3021842</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21253529" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21253529</a>.</span></div></li><li id="24" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Athyros VG, Katsiki N, Tziomalos K, Karagiannis A (2011). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242401" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?&quot;</a>. <em>The Open Cardiovascular Medicine Journal</em>. <strong>5</strong> : 226â€“230. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.2174%2F1874192401105010226" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.2174/1874192401105010226</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242401" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3242401</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22207888" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22207888</a>.</span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2025845" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2025845" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2025845</a></span></div></li><li id="27" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">VanValkinburgh, Danny; Kerndt, Connor C.; Hashmi, Muhammad F. (2025), <a href="https://www.ncbi.nlm.nih.gov/books/NBK482411/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Inotropes and Vasopressors&quot;</a>, <em>StatPearls</em> , Treasure Island (FL): StatPearls Publishing, <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29494018" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29494018</a>, retrieved 2025-03-26</span></div></li><li id="28" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Lim WY, Ahsan S, Papageorgiou N (September 2018). &quot;Heart and kidney failure: Two organs, two disease states?&quot;. <em>International Journal of Cardiology</em>. <strong>266</strong> : 193â€“194. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.ijcard.2018.04.044" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.ijcard.2018.04.044</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29887445" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29887445</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:47006200" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">47006200</a>.</span></div></li><li id="https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality</a></span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Cardiorenal_syndrome" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4" id="_R_" async=""></script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\"}]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Cardiorenal_syndrome\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Cardiorenal_syndrome\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Cardiorenal_syndrome\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T5f8c,"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"# Cardiorenal syndrome\n\n**Cardiorenal syndrome** (**CRS**) refers to the spectrum of disorders in which acute or chronic dysfunction of the heart or kidneys leads to acute or chronic dysfunction of the other.[1]\n\nThe condition is classified into five subtypes based on the primary organ dysfunction and whether the disease process is acute or chronic. The heart and the kidneys maintain hemodynamic stability and organ perfusion through an intricate network. CRS results from a complex interplay of hemodynamic alterations, neurohormonal activation, inflammatory mediators, and endothelial dysfunction, all contributing to progressive organ injury.[2] Cardiorenal syndrome is commonly associated with conditions such as heart failure, chronic kidney disease (CKD), acute kidney injury (AKI), and systemic hypertension.[3]\n\nManagement of CRS primarily focuses on addressing the underlying cause while mitigating the complications associated with the syndrome. Since volume overload is a predominant feature in most patients, treatment typically involves fluid removal, primarily through loop diuretics, with thiazides as adjuncts for diuretic resistant cases.[4] Ultrafiltration is reserved for refractory cases.[4] Depending on the case, additional therapies such as ACE inhibitors, angiotensin II receptor blockers, angiotensin receptor neprilysin inhibitors (ARNI), sodium-glucose cotransporter 2 (SGLT2) inhibitors, mineralocorticoid receptor antagonists, and inotropes may be utilized.[5][11][25][26] Despite available treatments, CRS remains associated with high morbidity and mortality.\n# Cardiorenal Syndrome\n\n## Signs and symptoms\n\nCardiorenal syndrome (CRS) encompasses a spectrum of disorders in which acute or chronic dysfunction in the heart or kidneys leads to dysfunction in the other organ. Therefore, the clinical signs and symptoms are consistent with congestive heart failure and chronic kidney disease. The clinical presentation of most patients typically involves fluid overload and worsening renal function. Patients may exhibit features of both acute and chronic forms, with acute presentations often including pulmonary or systemic congestion and acute kidney injury.[4] In chronic cases, symptoms develop more gradually, including progressive fatigue, exercise intolerance, nocturia, and uremic manifestations such as nausea, anorexia, and pruritus.\n\nSymptoms of peripheral edema and shortness of breath are common both in patients with CHF and CKD or a combination thereof. Patients will frequently exhibit signs of acute decompensated heart failure, such as volume overload characterized by peripheral edema, pulmonary congestion, jugular venous distension, and shortness of breath.[3] Prolonged effects of heart failure, such as fatigue and exercise intolerance, may also be present. Additional signs can include ascites, an S3 gallop, bibasilar rales, and in cases of low-output states, hypotension and cool extremities.\n\nSymptoms of cardiorenal syndrome often present with classic indicators of renal dysfunction. Increased serum levels of creatinine and BUN, as well as reduced urine production (oliguria), may indicate worsening renal function.[6] In advanced cases, electrolyte imbalances or uremia may contribute to confusion or altered mentation.\n## Risk factors\n\nThe primary risk factors for the development of cardiorenal syndrome are pre-existing cardiac or renal disease. The following risk factors have been associated with increased incidence of CRS.[5]\n\n### Clinical\n* Older age\n* Comorbid conditions (diabetes mellitus, uncontrolled hypertension, anemia)\n* Drugs (anti-inflammatory agents, diuretics, ACE inhibitors, ARBs)\n\n### Heart\n* History of heart failure with impaired left ventricular ejection fraction\n* Prior myocardial infarction\n* Elevated New York Heart Association (NYHA) functional class\n* Elevated cardiac troponins\n\n### Kidney\n* Chronic kidney disease (reduced eGFR, elevated BUN, creatinine, or cystatin)\n## Pathophysiology\n\nCardiorenal syndrome (CRS) pathophysiology involves a complex bidirectional interaction between the heart and kidneys. The underlying mechanisms are broadly categorized into hemodynamic and non-hemodynamic factors. Hemodynamic factors primarily include changes in blood flow, such as reduced cardiac output and elevated [central venous](Central_venous_pressure \"Central venous pressure\") or intra-abdominal pressures. Non-hemodynamic factors include [neurohormonal](Neurohormone \"Neurohormone\") activation, [oxidative stress](Oxidative_stress \"Oxidative stress\"), and [systemic inflammation](Systemic_inflammation \"Systemic inflammation\"). These mechanisms often act synergistically, contributing to the progressive dysfunction of both organs.[2]\n\n### Hemodynamic factors\n\nReduced [cardiac output](Cardiac_output \"Cardiac output\"), commonly due to heart failure or other cardiovascular conditions, leads to decreased renal perfusion.[8] Historically, this reduction in perfusion was considered the primary driver of kidney dysfunction in heart failure. However, recent studies suggest that [venous congestion](Venous_stasis \"Venous stasis\") may play an even more critical role. Heart failure increases central venous and intra-abdominal pressures, which are important regulators of renal blood flow.[9] Elevated venous pressures reduce the net glomerular filtration pressure, promoting renal injury.[10] These changes contribute to worsening volume overload and further deterioration of cardiac and renal function. \n\nThe [renin-angiotensin-aldosterone system](Renin%E2%80%93angiotensin_system \"Reninâ€“angiotensin system\") (RAAS) is activated in response to reduced renal perfusion. Although RAAS normally helps maintain blood pressure and organ perfusion, chronic over-activation leads to inappropriate sodium and water retention. This exacerbates volume overload and perpetuates a cycle of worsening heart and kidney function.[11][12]\n\n### Non-hemodynamic factors\n\nIn addition to hemodynamic changes, several non-hemodynamic mechanisms contribute to the progression of CRS. These include neurohormonal activation, oxidative stress, and systemic inflammation, all of which are associated with structural and functional deterioration in both the heart and kidneys.[13]\n\nNeurohormonal systems, primarily the RAAS and sympathetic nervous system (SNS), are activated in response to reduced renal perfusion.[13] In heart failure, these systems become over-activated, causing peripheral vasoconstriction and extracellular fluid retention.[12] Beyond hemodynamic effects, RAAS and SNS activation stimulate oxidative and inflammatory pathways and contribute to cardiac remodeling and progressive dysfunction.[13]\n\nOxidative stress and inflammation also play critical roles. Elevated levels of [reactive oxygen species](Reactive_oxygen_species \"Reactive oxygen species\") (ROS), [endothelin](Endothelin \"Endothelin\"), and [arginine vasopressin](Arginine_vasopressin \"Arginine vasopressin\") contribute to endothelial dysfunction, myocardial hypertrophy, and fibrosis, as well as to renal tubular injury and glomerular dysfunction.[14] An imbalance between [nitric oxide](Nitric_oxide \"Nitric oxide\") and ROS exacerbates endothelial dysfunction and impairs organ perfusion. There is a close interaction within these cardio-renal connectors as well as between these factors and the hemodynamic factors which makes the study of CRS pathophysiology complicated.[2]\n# Diagnosis\n\nDiagnosing cardiorenal syndrome (CRS) is challenging due to the complex and interconnected nature of cardiac and renal dysfunction. It is critical to diagnose CRS at an early stage in order to achieve optimal therapeutic efficacy. There is no specific test to diagnose cardiorenal syndrome. Instead, diagnosis relies on clinical evaluation, laboratory data, and imaging, often in the context of known heart failure, kidney disease, or both.[1] The diagnosis of heart failure requires the presence of clinical signs and symptoms supported by evidence of a structural or functional cardiac abnormality. This diagnostic requirement for cardiorenal syndrome includes similar evidence for both the heart and kidneys.[5]\n\n## Cardiac Biomarkers\n\nCardiac biomarkers can help to identify cardiac dysfunction in the evaluation for Cardiorenal syndrome. Brain natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are peptides elevated in the presence of cardiac stress and volume overload.[5] Cardiac troponin is a biomarker that can be useful to indicate ongoing myocardial damage and stress. The use of BNP, NT-proBNP, and troponin can be confounded by decreased renal clearance in patients with impaired renal function.[5] Despite the limitations, these biomarkers can help to identify cardiac dysfunction crucial to the diagnosis of CRS. Though less frequently used in clinical practice, Galectin-3 and ST2 (suppressor of tumorigenicity 2), markers of fibrosis and myocardial stress, can add prognostic value.[5]\n\n## Renal Biomarkers\n\nUnlike markers of heart damage or stress such as troponin, creatine kinase, natriuretic peptides, reliable markers for acute kidney injury are lacking. Recently, research has found several biomarkers that can be used for early detection of acute kidney injury before serious loss of organ function may occur. Several of these biomarkers include neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-B-D-glucosaminidase (NAG), Cystatin C, kidney injury molecule-1 (KIM-1), and tissue inhibitor of metalloproteinases-2/interleukin-6 finger-binding protein 7 (TIMP-2/IGFBP7) which have been shown to be involved in tubular damage.[9][5] Other biomarkers that have been shown to be useful include BNP, IL-18, and fatty acid binding protein (FABP).[9] However, there is great variability in the measurement of these biomarkers and their use in diagnosing CRS must be assessed.[15]\n\n## Non-Invasive Imaging\n\nThe diagnosis of Cardiorenal syndrome utilizes imaging to provide key insights into structural and functional changes in the heart and kidneys. Echocardiography is the primary tool to assess heart function and can provide data on heart chamber performance, valvular abnormalities, and estimates of filling pressures. Lung ultrasound is a commonly used bedside tool to identify pulmonary edema.[5] Imaging of the kidneys is commonly performed using ultrasound to assess size, structural changes, and perfusion.[5]\n# Classification\n\nRonco et al. first proposed a five-part classification system for CRS in 2008 which was also accepted at ADQI consensus conference in 2010.[1] These include: \n\n| Type | Inciting event | Secondary disturbance | Example |\n|-----|---------------|-----------------------|---------|\n| **Type 1** (*acute CRS*) | Abrupt worsening of heart function | kidney injury | acute [cardiogenic shock](Cardiogenic_shock \"Cardiogenic shock\") or [acute decompensation of chronic heart failure](Acute_decompensated_heart_failure \"Acute decompensated heart failure\") |\n| **Type 2** (*chronic CRS*) | Chronic abnormalities in heart function | progressive [chronic kidney disease](Chronic_kidney_disease \"Chronic kidney disease\") | [chronic heart failure](Chronic_heart_failure \"Chronic heart failure\") |\n| **Type 3** (*acute renocardiac syndrome*) | Abrupt worsening of kidney function | acute cardiac disorder (e.g. heart failure, [abnormal heart rhythm](Heart_arrhythmia \"Heart arrhythmia\"), or pulmonary edema) | [acute kidney failure](Acute_kidney_failure \"Acute kidney failure\") or [glomerulonephritis](Glomerulonephritis \"Glomerulonephritis\") |\n| **Type 4** (*chronic renocardiac syndrome*) | Chronic kidney disease | decreased cardiac function, cardiac hypertrophy and/or increased risk of adverse cardiovascular events | chronic glomerular disease |\n| **Type 5** (*secondary CRS*) | Systemic condition | both heart and kidney dysfunction | diabetes mellitus, [sepsis](Sepsis \"Sepsis\"), lupus |\n\n### Type 1: Acute cardio-renal syndrome\n\nAcute cardiorenal syndrome occurs in patients who experience an abrupt decrease in cardiac function, causing an acute kidney injury and/or dysfunction. The sudden reduction in kidney function is frequently caused by [acute decompensated heart failure](Acute_decompensated_heart_failure \"Acute decompensated heart failure\"), [acute coronary syndrome](Acute_coronary_syndrome \"Acute coronary syndrome\"), [cardiogenic shock](Cardiogenic_shock \"Cardiogenic shock\"), and/or low flow syndrome following cardiac surgery.[3] The extent of renal injury can vary, often causing [acute kidney injury (AKI)](Acute_kidney_injury \"Acute kidney injury\"), but it can also result in acute renal failure. Type 1 CRS carries the risk of advancing to more severe stages of chronic kidney disease and [end-stage renal disease (ESRD)](End-stage_renal_disease \"End-stage renal disease\").[16]\n\n### Type 2: Chronic cardio-renal syndrome\n\nType 2 CRS refers to the specific situation in which chronic heart dysfunction results in progressive kidney dysfunction. Cardiac conditions such as heart failure with reduced or preserved ejection fraction, atrial fibrillation, ischemic cardiomyopathy, and congenital heart disease can result in adaptive changes in renal perfusion and neurohormonal activation over time.[1][13] These conditions cause a time-dependent and progressive decline in renal function. \n\nThe distinction between CRS type 2 and CRS type 4 is based on the assumption that, also in advanced and chronic disease, two different pathophysiological mechanisms can be distinguished, whereas both CKD and HF often develop due to a common pathophysiological background, most notably [hypertension](Hypertension \"Hypertension\") and [diabetes mellitus](Diabetes_mellitus \"Diabetes mellitus\"). Furthermore, the feasibility of the distinction between CRS type 2 and 4 in terms of diagnosis can be questioned.[17]\n\n### Type 3: Acute reno-cardiac syndrome\n\nType 3 CRS involves a abrupt decrease in renal function resulting in an acute cardiac disorder. An example of type 3 CRS would be the development of [acute heart failure](Heart_failure \"Heart failure\"), [acute coronary syndrome](Acute_coronary_syndrome \"Acute coronary syndrome\") or [arrhythmia](Arrhythmia \"Arrhythmia\") following the onset of an AKI, or intrinsic kidney disease.[1] Drug-induced renal disease, [rhabdomyolysis](Rhabdomyolysis \"Rhabdomyolysis\"), and [acute nephritic syndromes](Nephritic_syndrome \"Nephritic syndrome\") have been associated with Type 3 CRS.[3]\n\n### Type 4: Chronic reno-cardiac syndrome\n\nType 4 cardiorenal syndrome is the development of chronic heart dysfunction as a result of chronic kidney disease. Many studies have found increased rates of cardiovascular disease in patients with CKD, that occur in a dose-dependent relationship, with the greatest reductions in GFR resulting in the greatest risk for CVD development.[16] The data from scientific literature indicates that CKD increases the risk for developing heart disease.[1]\n\n### Type 5: Secondary cardiorenal syndrome\n\nThis subtype of CRS refers to a separate condition resulting in simultaneous cardiac and renal systems dysfunction. These cases often involve a systemic illness such as [sepsis](Sepsis \"Sepsis\"), multiple traumas, [amyloidosis](Amyloidosis \"Amyloidosis\"), [sarcoidosis](Sarcoidosis \"Sarcoidosis\"), [diabetes mellitus](Diabetes \"Diabetes\"), [hepatitis b](Hepatitis_B \"Hepatitis B\"), [hepatitis c](Hepatitis_C \"Hepatitis C\"), [systemic lupus erythematosus (SLE)](Lupus \"Lupus\"), and significant burns, causing an abrupt decrease in both cardiac and renal function.[1] Type 5 CRS can also be the result of the administration of [chemotherapy medications](Chemotherapy \"Chemotherapy\") and the use of illicit substances such as [heroin](Heroin \"Heroin\") and [cocaine](Cocaine \"Cocaine\").[16][3]\n\nBraam et al. argue that classifying the CRS based on the order in which the organs are affected and the timeframe (acute vs chronic) is too simplistic and without a mechanistic classification it is difficult to study CRS.[2] They view the cardiorenal syndrome in a more holistic, integrative manner.[2][18] They defined the cardiorenal syndrome as a pathophysiological condition in which combined heart and kidney dysfunction amplifies progression of failure of the individual organ, by inducing similar pathophysiological mechanisms. Therefore, regardless of which organ fails first, the same neurohormonal systems are activated causing accelerated cardiovascular disease, and progression of damage and failure of both organs. These systems are broken down into two broad categories of \"hemodynamic factors\" and non-hemodynamic factors or \"cardiorenal connectors\".[2]\n# Management\n\nMedical management of patients with CRS is often challenging as the treatment of one organ system may adversely affect the other. Many of the medications used to treat heart failure may worsen kidney function. Chronic kidney disease has been shown to have an adverse effect on morbidity and mortality in patients with heart failure.[19] Historically, many of the most impactful clinical trials regarding heart failure management excluded patients with significant renal impairment, limiting early understanding of treatment in cardiorenal syndrome; however, recent trials have included CKD patients, enhancing evidence-based management.[](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063)[20][21] The management of cardiorenal syndrome will vary depending on the subtype, as well as individual patient considerations. \n\nPatients with kidney failure are less likely to get all guideline-based therapies. Patients with moderate CKD often received similar guideline-based care to those with normal kidney function, though with lower use of ACE inhibitors/ARBs and blood pressure control; severe CKD patients had more disparities. This highlights opportunities for healthcare providers to improve outcomes in CRS patients.[22]\n\n### Diuretics\n\nDiuretics play a crucial role in managing fluid overload in patients with acute heart failure, with or without CRS. Although not supported by data from large clinical trials like other heart failure treatments, the clinical best practices regarding diuretics remain uncertain. Diuretics are widely considered a standard of care to reduce volume overload caused by acute heart failure based on expert opinion alone.[5] Guidelines recommend using diuretics cautiously by using minimal required dosing and close monitoring in patients with kidney disease, as they may potentially cause dehydration and worsening renal function.[20] Loop diuretics are the primary agents used in heart failure. Diuretic resistance is frequently a challenge for physicians to overcome which they may tackle by changing the dosage, frequency, or adding a second drug.[23]\n\n### ACE Inhibitors, Angiotensin II receptor blockers (ARB)\n\nThe use of ACE inhibitors has long-term protective effects on kidney and heart tissue. Angiotensin inhibition with an ACE inhibitor or angiotensin II receptor blocker (ARB) is a standard part of treatment for heart failure. The use of ACE inhibitors and ARBs in heart failure has been shown to improve survival and reduce kidney dysfunction. However, they should be used with caution in patients with CRS and kidney failure. Although patients with kidney failure may experience slight deterioration of kidney function in the short term, the use of ACE inhibitors is shown to have prognostic benefit over the long term.[23] Studies have suggested that the use of ACEI alongside statins might be an effective regimen to prevent a substantial number of CRS cases in high-risk patients and improve survival and quality of life in these people. There are data suggesting combined use of statin and an ACEI improves clinical outcome more than a statin alone and considerably more than ACE inhibitor alone.[24]\n\n### Angiotensin receptor neprilysin inhibitors (ARNI)\n\nA class of drugs for the treatment of chronic heart failure, angiotensin receptor neprilysin inhibitors (ARNI), has emerged as an alternative to ACE inhibitors and ARBs. This drug class has the effects of an ARB, blocking the effects of angiotensin II, combined with the inhibition of the enzyme neprilysin, which prevents the breakdown of natriuretic peptides.[25] Clinical studies have shown the clinical benefits of ARNIs in patients with heart failure and chronic kidney disease, supporting their use.[5] ARNIs are recommended in guidelines for heart failure management applicable to CRS, with established use in HFrEF and emerging evidence in HFpEF with CKD.[](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063)\n\n### Sodium-glucose cotransporter 2 (SGLT2) Inhibitors\n\nSodium-glucose cotransporter 2 (SGLT2) inhibitors are medications commonly used in regimens for treating heart failure and preserving renal function. SGLT2 inhibitors function to block glucose reabsorption in the kidney. These agents have demonstrated cardiovascular and renal protective benefits, such as reducing volume overload and preventing kidney damage caused by inflammation and oxidative stress.[26]\n\n### Mineralocorticoid Receptor Antagonists (MRA)\n\nTreatment with an ACE inhibitor or ARB may not sufficiently suppress the RAAS system in the long term. Mineralocorticoid receptor antagonists may be added to the regimen to provide additional RAAS suppression, resulting in more significant long-term cardiorenal benefits.[5][11] Non-steroidal MRAs like finerenone provide additional cardiorenal benefits in CKD with type 2 diabetes and HF, reducing progression to ESRD and CV events.[](https://www.nejm.org/doi/full/10.1056/NEJMoa2025845)\n\n### Beta-adrenergic blockers\n\nBeta-blockers are commonly used in guideline-directed heart failure medication regimens and may also be used in the treatment of cardiorenal syndrome. By blocking the effects of epinephrine, beta-blockers reduce blood pressure and significantly improve mortality and hospitalization rates in patients with heart failure and chronic kidney disease.[13]\n\n### Ultrafiltration\n\nUltrafiltration involves the removal of fluid from the venous system via filtration, in a process similar to dialysis. Ultrafiltration is generally reserved for patients in acute decompensated heart failure that have volume overload resistant to diuretics.[5] Many case reports have shown improved kidney function with ultrafiltration, however the clinical value has yet to be established.[9][5]\n\n### Inotropes\n\nInotropes are a class of drugs that enhance the contractile force produced by the heart and the overall cardiac output.[27] Due to their mechanism, they have the potential to treat cardiorenal syndrome by improving heart function and reducing venous congestion. However, the efficacy of inotropes as a long-term therapy has yet to be proven. They may be used in patients with cardiorenal syndrome in the instance of cardiogenic shock.[11][5]\n\n### Cardiac Resynchronization Therapy (CRT)\n\nCRT, a form of cardiac pacing, helps to improve heart function by electrically activating the ventricles to synchronize their contractions.[5] CRT has been shown to improve renal response in patients with chronic kidney disease and congestive heart failure.[11]\n## Epidemiology\n\nKidney failure is very common in patients with congestive heart failure. AKI complicates approximately one-third of heart failure admissions, which remains the leading cause of hospitalization in the United States among adults over 65 years old as of 2024.[9][22] This not only drives hospitalizations but also increases the likelihood of ICU admission.[28] These complications result in longer hospital stays, higher mortality, and greater risk of readmission. Inpatient mortality is substantially higher in patients with severe renal dysfunction.[22] Increased hospital and ICU utilization also raises healthcare costs.[28] Patients with heart failure and renal impairment face significant economic burden from prolonged care. In heart failure patients, renal impairment is associated with more severe symptoms; for example, chronic kidney disease is present in approximately 40-60% of those with heart failure, contributing to cardiorenal syndrome.[5] Similarly, kidney failure adversely affects cardiovascular function. As of 2024, 51.5% of deaths among patients with end-stage kidney disease (with known cause) are attributable to cardiovascular disease.[](https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality)"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761882399904,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. (March 2010). [\\\"Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838681). _European Heart Journal_. **31** (6): 703â€“711\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/eurheartj/ehp507](https://doi.org/10.1093%2Feurheartj%2Fehp507). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2838681](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838681). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20037146](https://pubmed.ncbi.nlm.nih.gov/20037146).\",\"description\":\"1. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. (March 2010). [\\\"Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838681). _European Heart Journal_. **31** (6): 703â€“711\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/eurheartj/ehp507](https://doi.org/10.1093%2Feurheartj%2Fehp507). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2838681](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838681). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20037146](https://pubmed.ncbi.nlm.nih.gov/20037146).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838681\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ Braam B, Joles JA, Danishwar AH, Gaillard CA (January 2014). \\\"Cardiorenal syndrome--current understanding and future perspectives\\\". _Nature Reviews. Nephrology_. **10** (1): 48â€“55\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nrneph.2013.250](https://doi.org/10.1038%2Fnrneph.2013.250). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24247284](https://pubmed.ncbi.nlm.nih.gov/24247284). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [7556399](https://api.semanticscholar.org/CorpusID:7556399).\",\"description\":\"2. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ Braam B, Joles JA, Danishwar AH, Gaillard CA (January 2014). \\\"Cardiorenal syndrome--current understanding and future perspectives\\\". _Nature Reviews. Nephrology_. **10** (1): 48â€“55\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nrneph.2013.250](https://doi.org/10.1038%2Fnrneph.2013.250). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24247284](https://pubmed.ncbi.nlm.nih.gov/24247284). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [7556399](https://api.semanticscholar.org/CorpusID:7556399).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Ajibowo, Abimbola O.; Okobi, Okelue E.; Emore, Erhieyovbe; Soladoye, Elizabeth; Sike, Cherechi G.; Odoma, Victor A.; Bakare, Ibrahim O.; Kolawole, Olasunkanmi A.; Afolayan, Adebola; Okobi, Emeka; Chukwu, Chinyereadaeze; Ajibowo, Abimbola O.; Okobi, Okelue E.; Emore, Erhieyovbe; Soladoye, Elizabeth (2023-07-01). [\\\"Cardiorenal Syndrome: A Literature Review\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389294). _Cureus_. **15** (7): e41252. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.7759/cureus.41252](https://doi.org/10.7759%2Fcureus.41252). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2168-8184](https://search.worldcat.org/issn/2168-8184). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [10389294](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389294). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [37529809](https://pubmed.ncbi.nlm.nih.gov/37529809).\",\"description\":\"3. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Ajibowo, Abimbola O.; Okobi, Okelue E.; Emore, Erhieyovbe; Soladoye, Elizabeth; Sike, Cherechi G.; Odoma, Victor A.; Bakare, Ibrahim O.; Kolawole, Olasunkanmi A.; Afolayan, Adebola; Okobi, Emeka; Chukwu, Chinyereadaeze; Ajibowo, Abimbola O.; Okobi, Okelue E.; Emore, Erhieyovbe; Soladoye, Elizabeth (2023-07-01). [\\\"Cardiorenal Syndrome: A Literature Review\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389294). _Cureus_. **15** (7): e41252. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.7759/cureus.41252](https://doi.org/10.7759%2Fcureus.41252). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2168-8184](https://search.worldcat.org/issn/2168-8184). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [10389294](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389294). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [37529809](https://pubmed.ncbi.nlm.nih.gov/37529809).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389294\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"_**a**_ _**b**_ _**c**_ Thind, Guramrinder S.; Loehrke, Mark; Wilt, Jeffrey L. (March 2018). \\\"Acute cardiorenal syndrome: Mechanisms and clinical implications\\\". _Cleveland Clinic Journal of Medicine_. **85** (3): 231â€“239\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3949/ccjm.85a.17019](https://doi.org/10.3949%2Fccjm.85a.17019). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1939-2869](https://search.worldcat.org/issn/1939-2869). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29522391](https://pubmed.ncbi.nlm.nih.gov/29522391).\",\"description\":\"4. ^ _**a**_ _**b**_ _**c**_ Thind, Guramrinder S.; Loehrke, Mark; Wilt, Jeffrey L. (March 2018). \\\"Acute cardiorenal syndrome: Mechanisms and clinical implications\\\". _Cleveland Clinic Journal of Medicine_. **85** (3): 231â€“239\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3949/ccjm.85a.17019](https://doi.org/10.3949%2Fccjm.85a.17019). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1939-2869](https://search.worldcat.org/issn/1939-2869). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29522391](https://pubmed.ncbi.nlm.nih.gov/29522391).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ Rangaswami, Janani; Bhalla, Vivek; Blair, John E.A.; Chang, Tara I.; Costa, Salvatore; Lentine, Krista L.; Lerma, Edgar V.; Mezue, Kenechukwu; Molitch, Mark; Mullens, Wilfried; Ronco, Claudio; Tang, W.H. Wilson; McCullough, Peter A.; On behalf of the American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology (2019-04-16). [\\\"Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association\\\"](https://www.ahajournals.org/doi/10.1161/CIR.0000000000000664). _Circulation_. **139** (16): e840 â€“ e878. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1161/CIR.0000000000000664](https://doi.org/10.1161%2FCIR.0000000000000664). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30852913](https://pubmed.ncbi.nlm.nih.gov/30852913).\",\"description\":\"5. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ Rangaswami, Janani; Bhalla, Vivek; Blair, John E.A.; Chang, Tara I.; Costa, Salvatore; Lentine, Krista L.; Lerma, Edgar V.; Mezue, Kenechukwu; Molitch, Mark; Mullens, Wilfried; Ronco, Claudio; Tang, W.H. Wilson; McCullough, Peter A.; On behalf of the American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology (2019-04-16). [\\\"Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association\\\"](https://www.ahajournals.org/doi/10.1161/CIR.0000000000000664). _Circulation_. **139** (16): e840 â€“ e878. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1161/CIR.0000000000000664](https://doi.org/10.1161%2FCIR.0000000000000664). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30852913](https://pubmed.ncbi.nlm.nih.gov/30852913).\",\"url\":\"https://www.ahajournals.org/doi/10.1161/CIR.0000000000000664\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"** Ronco, Claudio; Cicoira, Mariantonietta; McCullough, Peter A. (2012-09-18). [\\\"Cardiorenal Syndrome Type 1: Pathophysiological Crosstalk Leading to Combined Heart and Kidney Dysfunction in the Setting of Acutely Decompensated Heart Failure\\\"](https://www.sciencedirect.com/science/article/pii/S0735109712019559). _Journal of the American College of Cardiology_. **60** (12): 1031â€“1042\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.jacc.2012.01.077](https://doi.org/10.1016%2Fj.jacc.2012.01.077). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0735-1097](https://search.worldcat.org/issn/0735-1097). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22840531](https://pubmed.ncbi.nlm.nih.gov/22840531).\",\"description\":\"6. **^** Ronco, Claudio; Cicoira, Mariantonietta; McCullough, Peter A. (2012-09-18). [\\\"Cardiorenal Syndrome Type 1: Pathophysiological Crosstalk Leading to Combined Heart and Kidney Dysfunction in the Setting of Acutely Decompensated Heart Failure\\\"](https://www.sciencedirect.com/science/article/pii/S0735109712019559). _Journal of the American College of Cardiology_. **60** (12): 1031â€“1042\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.jacc.2012.01.077](https://doi.org/10.1016%2Fj.jacc.2012.01.077). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0735-1097](https://search.worldcat.org/issn/0735-1097). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22840531](https://pubmed.ncbi.nlm.nih.gov/22840531).\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0735109712019559\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"** Tang WH, Mullens W (February 2010). [\\\"Cardiorenal syndrome in decompensated heart failure\\\"](https://tede.ufrrj.br/jspui/handle/jspui/2850). _Heart_. **96** (4): 255â€“260\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1136/hrt.2009.166256](https://doi.org/10.1136%2Fhrt.2009.166256). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19401280](https://pubmed.ncbi.nlm.nih.gov/19401280). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6371841](https://api.semanticscholar.org/CorpusID:6371841).\",\"description\":\"7. **^** Tang WH, Mullens W (February 2010). [\\\"Cardiorenal syndrome in decompensated heart failure\\\"](https://tede.ufrrj.br/jspui/handle/jspui/2850). _Heart_. **96** (4): 255â€“260\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1136/hrt.2009.166256](https://doi.org/10.1136%2Fhrt.2009.166256). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19401280](https://pubmed.ncbi.nlm.nih.gov/19401280). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6371841](https://api.semanticscholar.org/CorpusID:6371841).\",\"url\":\"https://tede.ufrrj.br/jspui/handle/jspui/2850\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"** Wang, Jin; Zhang, Weiguang; Wu, Lingling; Mei, Yan; Cui, Shaoyuan; Feng, Zhe; Chen, Xiangmei (2020-06-19). [\\\"New insights into the pathophysiological mechanisms underlying cardiorenal syndrome\\\"](https://www.aging-us.com/article/103354/text). _Aging_. **12** (12): 12422â€“12431\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.18632/aging.103354](https://doi.org/10.18632%2Faging.103354). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1945-4589](https://search.worldcat.org/issn/1945-4589). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7343447](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343447). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32561688](https://pubmed.ncbi.nlm.nih.gov/32561688).\",\"description\":\"8. **^** Wang, Jin; Zhang, Weiguang; Wu, Lingling; Mei, Yan; Cui, Shaoyuan; Feng, Zhe; Chen, Xiangmei (2020-06-19). [\\\"New insights into the pathophysiological mechanisms underlying cardiorenal syndrome\\\"](https://www.aging-us.com/article/103354/text). _Aging_. **12** (12): 12422â€“12431\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.18632/aging.103354](https://doi.org/10.18632%2Faging.103354). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1945-4589](https://search.worldcat.org/issn/1945-4589). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7343447](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343447). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32561688](https://pubmed.ncbi.nlm.nih.gov/32561688).\",\"url\":\"https://www.aging-us.com/article/103354/text\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Viswanathan G, Gilbert S (October 2010). [\\\"The cardiorenal syndrome: making the connection\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989717). _International Journal of Nephrology_. **2011** : 283137. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4061/2011/283137](https://doi.org/10.4061%2F2011%2F283137). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2989717](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989717). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21151533](https://pubmed.ncbi.nlm.nih.gov/21151533).\",\"description\":\"9. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Viswanathan G, Gilbert S (October 2010). [\\\"The cardiorenal syndrome: making the connection\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989717). _International Journal of Nephrology_. **2011** : 283137. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4061/2011/283137](https://doi.org/10.4061%2F2011%2F283137). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2989717](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989717). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21151533](https://pubmed.ncbi.nlm.nih.gov/21151533).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989717\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"** Kousa, Omar; Mullane, Ryan; Aboeata, Ahmed (2025), [\\\"Cardiorenal Syndrome\\\"](https://www.ncbi.nlm.nih.gov/books/NBK542305/), _StatPearls_ , Treasure Island (FL): StatPearls Publishing, [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [31194445](https://pubmed.ncbi.nlm.nih.gov/31194445), retrieved 2025-03-22\",\"description\":\"10. **^** Kousa, Omar; Mullane, Ryan; Aboeata, Ahmed (2025), [\\\"Cardiorenal Syndrome\\\"](https://www.ncbi.nlm.nih.gov/books/NBK542305/), _StatPearls_ , Treasure Island (FL): StatPearls Publishing, [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [31194445](https://pubmed.ncbi.nlm.nih.gov/31194445), retrieved 2025-03-22\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK542305/\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ Verma, Deepak; Firoz, Amena; Garlapati, Sameer Krishna Prasad; Sai Charaan Reddy Sathi, Thanmay; Haris, Muhammad; Dhungana, Bibek; Ray, Barun; Shah, Gunjan; Kc, Bibek; Paudel, Palak (2021-08-17). [\\\"Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448169). _Cureus_. **13** (8): e17240. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.7759/cureus.17240](https://doi.org/10.7759%2Fcureus.17240). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2168-8184](https://search.worldcat.org/issn/2168-8184). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8448169](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448169). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34540466](https://pubmed.ncbi.nlm.nih.gov/34540466).\",\"description\":\"11. ^ _**a**_ _**b**_ _**c**_ _**d**_ Verma, Deepak; Firoz, Amena; Garlapati, Sameer Krishna Prasad; Sai Charaan Reddy Sathi, Thanmay; Haris, Muhammad; Dhungana, Bibek; Ray, Barun; Shah, Gunjan; Kc, Bibek; Paudel, Palak (2021-08-17). [\\\"Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448169). _Cureus_. **13** (8): e17240. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.7759/cureus.17240](https://doi.org/10.7759%2Fcureus.17240). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2168-8184](https://search.worldcat.org/issn/2168-8184). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8448169](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448169). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34540466](https://pubmed.ncbi.nlm.nih.gov/34540466).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448169\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"_**a**_ _**b**_ Ceravolo, Giorgia; Macchia, Tommaso La; Cuppari, Caterina; Dipasquale, Valeria; Gambadauro, Antonella; Casto, Celeste; Ceravolo, Maria Domenica; Cutrupi, Maricia; CalabrÃ², Maria Pia; Borgia, Paola; Piccolo, Gianluca; Mancuso, Alessio; Albiero, Remo; Chimenz, Roberto (2021-06-22). [\\\"Update on the Classification and Pathophysiological Mechanisms of Pediatric Cardiorenal Syndromes\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305733). _Children_. **8** (7): 528. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3390/children8070528](https://doi.org/10.3390%2Fchildren8070528). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2227-9067](https://search.worldcat.org/issn/2227-9067). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8305733](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305733). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34206173](https://pubmed.ncbi.nlm.nih.gov/34206173).\",\"description\":\"12. ^ _**a**_ _**b**_ Ceravolo, Giorgia; Macchia, Tommaso La; Cuppari, Caterina; Dipasquale, Valeria; Gambadauro, Antonella; Casto, Celeste; Ceravolo, Maria Domenica; Cutrupi, Maricia; CalabrÃ², Maria Pia; Borgia, Paola; Piccolo, Gianluca; Mancuso, Alessio; Albiero, Remo; Chimenz, Roberto (2021-06-22). [\\\"Update on the Classification and Pathophysiological Mechanisms of Pediatric Cardiorenal Syndromes\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305733). _Children_. **8** (7): 528. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3390/children8070528](https://doi.org/10.3390%2Fchildren8070528). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2227-9067](https://search.worldcat.org/issn/2227-9067). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8305733](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305733). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34206173](https://pubmed.ncbi.nlm.nih.gov/34206173).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305733\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Raina, Rupesh; Nair, Nikhil; Chakraborty, Ronith; Nemer, Lena; Dasgupta, Rahul; Varian, Kenneth (2020). [\\\"An Update on the Pathophysiology and Treatment of Cardiorenal Syndrome\\\"](https://www.cardiologyres.org/index.php/Cardiologyres/article/view/955/1029). _Cardiology Research_. **11** (2): 76â€“88\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.14740/cr955](https://doi.org/10.14740%2Fcr955). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1923-2829](https://search.worldcat.org/issn/1923-2829). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7092771](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092771). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32256914](https://pubmed.ncbi.nlm.nih.gov/32256914).\",\"description\":\"13. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Raina, Rupesh; Nair, Nikhil; Chakraborty, Ronith; Nemer, Lena; Dasgupta, Rahul; Varian, Kenneth (2020). [\\\"An Update on the Pathophysiology and Treatment of Cardiorenal Syndrome\\\"](https://www.cardiologyres.org/index.php/Cardiologyres/article/view/955/1029). _Cardiology Research_. **11** (2): 76â€“88\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.14740/cr955](https://doi.org/10.14740%2Fcr955). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1923-2829](https://search.worldcat.org/issn/1923-2829). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7092771](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092771). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32256914](https://pubmed.ncbi.nlm.nih.gov/32256914).\",\"url\":\"https://www.cardiologyres.org/index.php/Cardiologyres/article/view/955/1029\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"** Pokhrel N, Maharjan N, Dhakal B, Arora RR (2008). [\\\"Cardiorenal syndrome: A literature review\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663478). _Experimental and Clinical Cardiology_. **13** (4): 165â€“170\\\\. [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2663478](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663478). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19343160](https://pubmed.ncbi.nlm.nih.gov/19343160).\",\"description\":\"14. **^** Pokhrel N, Maharjan N, Dhakal B, Arora RR (2008). [\\\"Cardiorenal syndrome: A literature review\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663478). _Experimental and Clinical Cardiology_. **13** (4): 165â€“170\\\\. [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2663478](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663478). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19343160](https://pubmed.ncbi.nlm.nih.gov/19343160).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663478\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"** Expert Group on Biomarkers (May 2015). [\\\"Biomarkers in Cardiology - Part 2: In Coronary Heart Disease, Valve Disease and Special Situations\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495448). _Arquivos Brasileiros de Cardiologia_. **104** (5): 337â€“346\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.5935/abc.20150061](https://doi.org/10.5935%2Fabc.20150061). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4495448](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495448). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26083777](https://pubmed.ncbi.nlm.nih.gov/26083777).\",\"description\":\"15. **^** Expert Group on Biomarkers (May 2015). [\\\"Biomarkers in Cardiology - Part 2: In Coronary Heart Disease, Valve Disease and Special Situations\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495448). _Arquivos Brasileiros de Cardiologia_. **104** (5): 337â€“346\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.5935/abc.20150061](https://doi.org/10.5935%2Fabc.20150061). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4495448](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495448). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26083777](https://pubmed.ncbi.nlm.nih.gov/26083777).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495448\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"_**a**_ _**b**_ _**c**_ McCullough, Peter A. (2011). [\\\"Cardiorenal Syndromes: Pathophysiology to Prevention\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995900). _International Journal of Nephrology_. **2011** : 1â€“10\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4061/2011/762590](https://doi.org/10.4061%2F2011%2F762590). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2090-214X](https://search.worldcat.org/issn/2090-214X). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2995900](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995900). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21151537](https://pubmed.ncbi.nlm.nih.gov/21151537).\",\"description\":\"16. ^ _**a**_ _**b**_ _**c**_ McCullough, Peter A. (2011). [\\\"Cardiorenal Syndromes: Pathophysiology to Prevention\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995900). _International Journal of Nephrology_. **2011** : 1â€“10\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4061/2011/762590](https://doi.org/10.4061%2F2011%2F762590). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2090-214X](https://search.worldcat.org/issn/2090-214X). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2995900](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995900). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21151537](https://pubmed.ncbi.nlm.nih.gov/21151537).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995900\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"** Di Lullo L, Bellasi A, Barbera V, Russo D, Russo L, Di Iorio B, et al. (2017-03-01). [\\\"Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415026). _Indian Heart Journal_. **69** (2): 255â€“265\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ihj.2017.01.005](https://doi.org/10.1016%2Fj.ihj.2017.01.005). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5415026](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415026). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28460776](https://pubmed.ncbi.nlm.nih.gov/28460776).\",\"description\":\"17. **^** Di Lullo L, Bellasi A, Barbera V, Russo D, Russo L, Di Iorio B, et al. (2017-03-01). [\\\"Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415026). _Indian Heart Journal_. **69** (2): 255â€“265\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ihj.2017.01.005](https://doi.org/10.1016%2Fj.ihj.2017.01.005). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5415026](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415026). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28460776](https://pubmed.ncbi.nlm.nih.gov/28460776).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415026\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"** Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B (January 2005). [\\\"The severe cardiorenal syndrome: 'Guyton revisited'\\\"](https://doi.org/10.1093%2Feurheartj%2Fehi020). _European Heart Journal_. **26** (1): 11â€“17\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/eurheartj/ehi020](https://doi.org/10.1093%2Feurheartj%2Fehi020). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15615794](https://pubmed.ncbi.nlm.nih.gov/15615794).\",\"description\":\"18. **^** Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B (January 2005). [\\\"The severe cardiorenal syndrome: 'Guyton revisited'\\\"](https://doi.org/10.1093%2Feurheartj%2Fehi020). _European Heart Journal_. **26** (1): 11â€“17\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/eurheartj/ehi020](https://doi.org/10.1093%2Feurheartj%2Fehi020). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15615794](https://pubmed.ncbi.nlm.nih.gov/15615794).\",\"url\":\"https://doi.org/10.1093%2Feurheartj%2Fehi020\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"** McDonagh, Theresa A; Metra, Marco; Adamo, Marianna; Gardner, Roy S; Baumbach, Andreas; BÃ¶hm, Michael; Burri, Haran; Butler, Javed; ÄŒelutkienÄ—, Jelena; Chioncel, Ovidiu; Cleland, John G F; Coats, Andrew J S; Crespo-Leiro, Maria G; Farmakis, Dimitrios; Gilard, Martine (2021-12-21). [\\\"Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC\\\"](https://academic.oup.com/eurheartj/article/42/48/4901/6397185). _European Heart Journal_. **42** (48): 4901. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/eurheartj/ehab670](https://doi.org/10.1093%2Feurheartj%2Fehab670). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0195-668X](https://search.worldcat.org/issn/0195-668X).\",\"description\":\"19. **^** McDonagh, Theresa A; Metra, Marco; Adamo, Marianna; Gardner, Roy S; Baumbach, Andreas; BÃ¶hm, Michael; Burri, Haran; Butler, Javed; ÄŒelutkienÄ—, Jelena; Chioncel, Ovidiu; Cleland, John G F; Coats, Andrew J S; Crespo-Leiro, Maria G; Farmakis, Dimitrios; Gilard, Martine (2021-12-21). [\\\"Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC\\\"](https://academic.oup.com/eurheartj/article/42/48/4901/6397185). _European Heart Journal_. **42** (48): 4901. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/eurheartj/ehab670](https://doi.org/10.1093%2Feurheartj%2Fehab670). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0195-668X](https://search.worldcat.org/issn/0195-668X).\",\"url\":\"https://academic.oup.com/eurheartj/article/42/48/4901/6397185\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"_**a**_ _**b**_ Damman, Kevin; Tang, W. H. Wilson; Felker, G. Michael; Lassus, Johan; Zannad, Faiez; Krum, Henry; McMurray, John J. V. (2014-03-11). [\\\"Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data\\\"](https://linkinghub.elsevier.com/retrieve/pii/S0735109713064255). _Journal of the American College of Cardiology_. **63** (9): 853â€“871\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.jacc.2013.11.031](https://doi.org/10.1016%2Fj.jacc.2013.11.031). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0735-1097](https://search.worldcat.org/issn/0735-1097).\",\"description\":\"20. ^ _**a**_ _**b**_ Damman, Kevin; Tang, W. H. Wilson; Felker, G. Michael; Lassus, Johan; Zannad, Faiez; Krum, Henry; McMurray, John J. V. (2014-03-11). [\\\"Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data\\\"](https://linkinghub.elsevier.com/retrieve/pii/S0735109713064255). _Journal of the American College of Cardiology_. **63** (9): 853â€“871\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.jacc.2013.11.031](https://doi.org/10.1016%2Fj.jacc.2013.11.031). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0735-1097](https://search.worldcat.org/issn/0735-1097).\",\"url\":\"https://linkinghub.elsevier.com/retrieve/pii/S0735109713064255\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"** Gnanaraj J, Radhakrishnan J (2016-08-31). [\\\"Cardio-renal syndrome\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007748). _F1000Research_. **5** : F1000 Faculty Revâ€“2123. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.12688/f1000research.8004.1](https://doi.org/10.12688%2Ff1000research.8004.1). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5007748](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007748). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [27635229](https://pubmed.ncbi.nlm.nih.gov/27635229).\",\"description\":\"21. **^** Gnanaraj J, Radhakrishnan J (2016-08-31). [\\\"Cardio-renal syndrome\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007748). _F1000Research_. **5** : F1000 Faculty Revâ€“2123. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.12688/f1000research.8004.1](https://doi.org/10.12688%2Ff1000research.8004.1). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5007748](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007748). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [27635229](https://pubmed.ncbi.nlm.nih.gov/27635229).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007748\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"_**a**_ _**b**_ Patel UD, Hernandez AF, Liang L, Peterson ED, LaBresh KA, Yancy CW, et al. (October 2008). [\\\"Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2604122). _American Heart Journal_. **156** (4): 674â€“681\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ahj.2008.05.028](https://doi.org/10.1016%2Fj.ahj.2008.05.028). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2604122](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2604122). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18946892](https://pubmed.ncbi.nlm.nih.gov/18946892).\",\"description\":\"22. ^ _**a**_ _**b**_ Patel UD, Hernandez AF, Liang L, Peterson ED, LaBresh KA, Yancy CW, et al. (October 2008). [\\\"Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2604122). _American Heart Journal_. **156** (4): 674â€“681\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ahj.2008.05.028](https://doi.org/10.1016%2Fj.ahj.2008.05.028). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2604122](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2604122). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18946892](https://pubmed.ncbi.nlm.nih.gov/18946892).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2604122\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"_**a**_ _**b**_ Shah BN, Greaves K (December 2010). [\\\"The cardiorenal syndrome: a review\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021842). _International Journal of Nephrology_. **2011** : 920195. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4061/2011/920195](https://doi.org/10.4061%2F2011%2F920195). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3021842](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021842). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21253529](https://pubmed.ncbi.nlm.nih.gov/21253529).\",\"description\":\"23. ^ _**a**_ _**b**_ Shah BN, Greaves K (December 2010). [\\\"The cardiorenal syndrome: a review\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021842). _International Journal of Nephrology_. **2011** : 920195. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4061/2011/920195](https://doi.org/10.4061%2F2011%2F920195). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3021842](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021842). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21253529](https://pubmed.ncbi.nlm.nih.gov/21253529).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021842\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"** Athyros VG, Katsiki N, Tziomalos K, Karagiannis A (2011). [\\\"Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242401). _The Open Cardiovascular Medicine Journal_. **5** : 226â€“230\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2174/1874192401105010226](https://doi.org/10.2174%2F1874192401105010226). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3242401](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242401). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22207888](https://pubmed.ncbi.nlm.nih.gov/22207888).\",\"description\":\"24. **^** Athyros VG, Katsiki N, Tziomalos K, Karagiannis A (2011). [\\\"Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242401). _The Open Cardiovascular Medicine Journal_. **5** : 226â€“230\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2174/1874192401105010226](https://doi.org/10.2174%2F1874192401105010226). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3242401](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242401). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22207888](https://pubmed.ncbi.nlm.nih.gov/22207888).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242401\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"** Nicolas, Diala; Kerndt, Connor C.; Patel, Preeti; Reed, Mirembe (2025), [\\\"Sacubitril-Valsartan\\\"](https://www.ncbi.nlm.nih.gov/books/NBK507904/), _StatPearls_ , Treasure Island (FL): StatPearls Publishing, [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29939681](https://pubmed.ncbi.nlm.nih.gov/29939681), retrieved 2025-03-25\",\"description\":\"25. **^** Nicolas, Diala; Kerndt, Connor C.; Patel, Preeti; Reed, Mirembe (2025), [\\\"Sacubitril-Valsartan\\\"](https://www.ncbi.nlm.nih.gov/books/NBK507904/), _StatPearls_ , Treasure Island (FL): StatPearls Publishing, [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29939681](https://pubmed.ncbi.nlm.nih.gov/29939681), retrieved 2025-03-25\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK507904/\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"** Margonato, Davide; Galati, Giuseppe; Mazzetti, Simone; Cannistraci, Rosa; Perseghin, Gianluca; Margonato, Alberto; Mortara, Andrea (2021-03-01). [\\\"Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895775). _Heart Failure Reviews_. **26** (2): 337â€“345\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s10741-020-10024-2](https://doi.org/10.1007%2Fs10741-020-10024-2). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1573-7322](https://search.worldcat.org/issn/1573-7322). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7895775](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895775). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32901315](https://pubmed.ncbi.nlm.nih.gov/32901315).\",\"description\":\"26. **^** Margonato, Davide; Galati, Giuseppe; Mazzetti, Simone; Cannistraci, Rosa; Perseghin, Gianluca; Margonato, Alberto; Mortara, Andrea (2021-03-01). [\\\"Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895775). _Heart Failure Reviews_. **26** (2): 337â€“345\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s10741-020-10024-2](https://doi.org/10.1007%2Fs10741-020-10024-2). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1573-7322](https://search.worldcat.org/issn/1573-7322). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7895775](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895775). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32901315](https://pubmed.ncbi.nlm.nih.gov/32901315).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895775\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"** VanValkinburgh, Danny; Kerndt, Connor C.; Hashmi, Muhammad F. (2025), [\\\"Inotropes and Vasopressors\\\"](https://www.ncbi.nlm.nih.gov/books/NBK482411/), _StatPearls_ , Treasure Island (FL): StatPearls Publishing, [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29494018](https://pubmed.ncbi.nlm.nih.gov/29494018), retrieved 2025-03-26\",\"description\":\"27. **^** VanValkinburgh, Danny; Kerndt, Connor C.; Hashmi, Muhammad F. (2025), [\\\"Inotropes and Vasopressors\\\"](https://www.ncbi.nlm.nih.gov/books/NBK482411/), _StatPearls_ , Treasure Island (FL): StatPearls Publishing, [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29494018](https://pubmed.ncbi.nlm.nih.gov/29494018), retrieved 2025-03-26\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK482411/\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"_**a**_ _**b**_ Lim WY, Ahsan S, Papageorgiou N (September 2018). \\\"Heart and kidney failure: Two organs, two disease states?\\\". _International Journal of Cardiology_. **266** : 193â€“194\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ijcard.2018.04.044](https://doi.org/10.1016%2Fj.ijcard.2018.04.044). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29887445](https://pubmed.ncbi.nlm.nih.gov/29887445). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [47006200](https://api.semanticscholar.org/CorpusID:47006200).\",\"description\":\"28. ^ _**a**_ _**b**_ Lim WY, Ahsan S, Papageorgiou N (September 2018). \\\"Heart and kidney failure: Two organs, two disease states?\\\". _International Journal of Cardiology_. **266** : 193â€“194\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ijcard.2018.04.044](https://doi.org/10.1016%2Fj.ijcard.2018.04.044). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29887445](https://pubmed.ncbi.nlm.nih.gov/29887445). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [47006200](https://api.semanticscholar.org/CorpusID:47006200).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"** McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW (March 2004). [\\\"Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study\\\"](https://doi.org/10.1161%2F01.cir.0000116764.53225.a9). _Circulation_. **109** (8): 1004â€“1009\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1161/01.cir.0000116764.53225.a9](https://doi.org/10.1161%2F01.cir.0000116764.53225.a9). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [14769700](https://pubmed.ncbi.nlm.nih.gov/14769700).\",\"description\":\"29. **^** McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW (March 2004). [\\\"Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study\\\"](https://doi.org/10.1161%2F01.cir.0000116764.53225.a9). _Circulation_. **109** (8): 1004â€“1009\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1161/01.cir.0000116764.53225.a9](https://doi.org/10.1161%2F01.cir.0000116764.53225.a9). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [14769700](https://pubmed.ncbi.nlm.nih.gov/14769700).\",\"url\":\"https://doi.org/10.1161%2F01.cir.0000116764.53225.a9\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"** National Institutes of Health. [\\\"National Institute of Diabetes and Digestive and Kidney disease\\\"](https://web.archive.org/web/20070213232827/http://www.usrds.org/). Annual Data Report. Archived from [the original](http://www.usrds.org/) on 2007-02-13. Retrieved 22 November 2013.\",\"description\":\"30. **^** National Institutes of Health. [\\\"National Institute of Diabetes and Digestive and Kidney disease\\\"](https://web.archive.org/web/20070213232827/http://www.usrds.org/). Annual Data Report. Archived from [the original](http://www.usrds.org/) on 2007-02-13. Retrieved 22 November 2013.\",\"url\":\"https://web.archive.org/web/20070213232827/http://www.usrds.org/\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"Depending on the case, additional therapies such as [ACE inhibitors](ACE_inhibitor \\\"ACE inhibitor\\\"), [angiotensin II receptor blockers](Angiotensin_II_receptor_blocker \\\"Angiotensin II receptor blocker\\\"), [mineralocorticoid receptor antagonists](Mineralocorticoid_receptor_antagonist \\\"Mineralocorticoid receptor antagonist\\\"), and [inotropes](Inotrope \\\"Inotrope\\\") may be utilized.\",\"explanation\":\"The management description omits key contemporary therapies like angiotensin receptor neprilysin inhibitors (ARNI, e.g., sacubitril-valsartan) and sodium-glucose cotransporter 2 (SGLT2) inhibitors, which have become standard in cardiorenal syndrome treatment since 2019, particularly for heart failure with renal involvement. This creates a knowledge gap in timeliness, as these are recommended in current guidelines (e.g., AHA/ESC updates post-2019) and reduce cardiorenal events.\",\"fixedText\":\"Add ARNI and SGLT2 inhibitors to the list of additional therapies, citing recent sources, to reflect current standard care as of 2025.\",\"evidenceSource\":\"Ref 5 (AHA 2019); Ref 11 (2021 emerging treatments); StatPearls (updated 2025)\"},{\"criticality\":\"Non-Critical\",\"issueType\":\"Formatting\",\"problematicText\":\"Cardiorenal syndrome --- [Specialty](Medical_specialty \\\"Medical specialty\\\")| [Nephrology](Nephrology \\\"Nephrology\\\"), [cardiology](Cardiology \\\"Cardiology\\\") [![Edit this on Wikidata](./_assets_/OOjs_UI_icon_edit-ltr-progressive.svg.png)](https://www.wikidata.org/wiki/Q5038718?uselang=en#P1995 \\\"Edit this on Wikidata\\\")\",\"explanation\":\"This appears to be an infobox or sidebar element misplaced in the intro text; it should be removed from the main content as it is not substantive article text.\",\"fixedText\":\"Remove the entire infobox block, retaining only the main paragraph content under the heading.\",\"evidenceSource\":\"N/A\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch | Scope/Applicability Misstatement\",\"problematicText\":\"The clinical presentation of most patients typically involves [fluid overload](Hypervolemia \\\"Hypervolemia\\\"), reduced [cardiac output](Cardiac_output \\\"Cardiac output\\\"), and worsening renal function.\",\"explanation\":\"The claim that reduced cardiac output is typical in most patients with CRS is not supported by sources. In acute CRS (type 1), cardiac output is often preserved or only mildly reduced in some cases, with congestion and elevated venous pressures being more prominent mechanisms leading to renal dysfunction. This misstates the hemodynamic profile, potentially leading to incorrect clinical understanding.\",\"fixedText\":\"Revise to: \\\"The clinical presentation of most patients typically involves fluid overload and worsening renal function.\\\" Remove reference to reduced cardiac output as it is not a universal or typical feature.\",\"evidenceSource\":\"[4] Thind et al. (2018): \\\"Although cardiac output may be mildly reduced in some cases of acute heart failure, systemic perfusion is enough to maintain organ function.\\\"\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"The section focuses primarily on acute presentations (type 1 CRS) and general heart failure signs, but CRS includes chronic forms (types 2 and 4) and reno-cardiac types (3 and 5). Missing details on insidious symptoms in chronic CRS, such as progressive fatigue, nocturia, or uremic symptoms (nausea, pruritus), and how presentations differ by type, which could limit comprehensive understanding given the article's classification section later.\",\"fixedText\":\"Add a brief paragraph or sentences distinguishing acute vs. chronic presentations and common renal-specific symptoms beyond labs, e.g., oliguria, uremia signs, to cover the spectrum without duplicating classification details.\",\"evidenceSource\":\"[5] AHA Scientific Statement (2019); StatPearls (updated 2025)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No problematic text; missing key biomarker.\",\"explanation\":\"NT-proBNP is a standard cardiac biomarker used alongside BNP for diagnosing heart failure and assessing prognosis in CRS, particularly in patients with renal impairment where it provides complementary information. Its omission represents a knowledge gap in comprehensive coverage of cardiac biomarkers.\",\"fixedText\":\"Add mention of NT-proBNP as a key cardiac biomarker, noting its utility in renal impairment, cited to [5].\",\"evidenceSource\":\"[5]\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No problematic text; incomplete list of renal biomarkers.\",\"explanation\":\"TIMP-2/IGFBP7 is an established biomarker for predicting AKI risk in high-risk patients, including those with CRS, and is FDA-approved for clinical use. Its absence is a knowledge gap, as it is recommended in guidelines for early detection.\",\"fixedText\":\"Add TIMP-2/IGFBP7 to the list of renal biomarkers for early AKI detection in CRS context, cited to [5].\",\"evidenceSource\":\"[5]\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Lung ultrasound has recently emerged as a commonly used bedside tool\\\"\",\"explanation\":\"The term \\\"recently\\\" is vague and outdated; as of 2025, lung ultrasound is a well-established standard tool for assessing pulmonary congestion in heart failure and CRS, not emerging.\",\"fixedText\":\"Remove \\\"recently emerged\\\" and state it as a commonly used bedside tool.\",\"evidenceSource\":\"[5]\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Patients who have moderate to severe CKD was seen to have similar care when compared to those patients who had normal kidney function.\",\"explanation\":\"The cited source [22] indicates that moderate to severe CKD patients often received similar care but with notable exceptions, such as lower use of ACEI/ARB (OR 0.47 for moderate, 0.19 for severe) and reduced blood pressure control. The claim overstates similarity without acknowledging disparities, potentially misleading on treatment gaps in CRS.\",\"fixedText\":\"Revise to: \\\"Patients with moderate CKD often received similar guideline-based care to those with normal kidney function, though with lower use of ACE inhibitors/ARBs and blood pressure control; severe CKD patients had more disparities.\\\"\",\"evidenceSource\":\"[22] Patel et al. 2008\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Many of the most impactful clinical trials regarding heart failure management have excluded patients with significant renal impairment, limiting the understanding of treatment in cardiorenal syndrome.[20][21]\",\"explanation\":\"This claim, based on 2014-2016 sources, is outdated as of 2025. Recent trials (e.g., DAPA-HF 2019, EMPEROR-Reduced 2020, PARADIGM-HF subgroup analyses) have included CKD patients, improving evidence for CRS management in HF with renal impairment per 2022 AHA/ACC/HFSA guidelines.\",\"fixedText\":\"Update to: \\\"Historically, many impactful heart failure trials excluded patients with significant renal impairment, limiting early understanding of CRS treatments; however, recent trials have included CKD patients, enhancing evidence-based management.[](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063)\\\"\",\"evidenceSource\":\"2022 AHA/ACC/HFSA Guideline https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"The guidelines regarding the clinical use of ARNIs in cardiorenal syndrome are still evolving.\",\"explanation\":\"As of 2025, ARNI use is established as Class I recommendation in 2022 AHA/ACC/HFSA guidelines for HFrEF (common in CRS Type 1/2), with CKD considerations (e.g., dose adjustment for eGFR \u0026lt;30). For HFpEF (relevant to some CRS), it's evolving but supported by EMPEROR-Preserved and PARAGON-HF. The claim understates current guideline status.\",\"fixedText\":\"Revise to: \\\"ARNIs are recommended in guidelines for heart failure management applicable to CRS, with established use in HFrEF and emerging evidence in HFpEF with CKD.[](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063)\\\"\",\"evidenceSource\":\"2022 AHA/ACC/HFSA Guideline https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063; StatPearls 2025 [25]\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific quote; general section]\",\"explanation\":\"The section lacks updates on recent therapies like finerenone (non-steroidal MRA) approved for CKD in HF (FIDELIO-DKD 2020, FIGARO 2021; 2023 ESC guidelines Class I for CKD with albuminuria), which addresses cardiorenal protection beyond traditional MRAs.\",\"fixedText\":\"Add under MRA subsection: \\\"Non-steroidal MRAs like finerenone provide additional cardiorenal benefits in CKD with type 2 diabetes and HF, reducing progression to ESRD and CV events.[](https://www.nejm.org/doi/full/10.1056/NEJMoa2025845)\\\"\",\"evidenceSource\":\"2023 ESC Guidelines for CVD in CKD https://academic.oup.com/eurheartj/article/44/39/4120/7271950\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"It was estimated that about 44% of deaths in patients with end-stage kidney failure (ESKF) are due to cardiovascular disease.[30]\",\"explanation\":\"The cited source (ref 30) is an archived USRDS report from around 2007. Recent data from the 2024 USRDS Annual Data Report indicates that 51.5% of deaths among patients with end-stage renal disease (known cause) are due to cardiovascular disease, including stroke, making the original figure outdated and potentially misleading for current epidemiology.\",\"fixedText\":\"Update the statistic to \\\"51.5% as of 2024\\\" and cite the 2024 USRDS report instead of or in addition to ref 30.\",\"evidenceSource\":\"USRDS 2024 Annual Data Report [](https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Another study found that 39% of patients in NYHA class 4 and 31% of patients in NYHA class 3 had severely impaired kidney function.[29]\",\"explanation\":\"The cited source (McAlister et al., 2004, ref 29) does not explicitly state these exact percentages in the accessible text; while commonly attributed to this study in secondary sources, direct verification shows only general associations between NYHA class and renal impairment without these specific figures, risking inaccuracy.\",\"fixedText\":\"Remove or rephrase the specific percentages unless confirmed; replace with supported general statement on association between NYHA class and renal impairment, citing ref 5 or similar.\",\"evidenceSource\":\"Direct review of ref 29; secondary citations like Rangaswami et al. (2019, ref 5)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"The section focuses on older US data and lacks recent global or CRS-specific prevalence/incidence statistics, temporal trends, and broader impacts (e.g., rising incidence in younger populations). Recent updates as of 2024-2025 show CRS affecting 40-60% of heart failure patients, with increasing hospitalizations.\",\"fixedText\":\"Add sentences on recent prevalence (e.g., ~50% of HF patients have CKD contributing to CRS) and note global burden, with citations.\",\"evidenceSource\":\"AHA 2024 Heart Disease and Stroke Statistics [](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001209); USRDS 2024\"}],\"slug\":\"Cardiorenal_syndrome\",\"title\":\"Cardiorenal syndrome\",\"content\":\"$1f\",\"description\":\"Cardiorenal syndrome\\n\\nCardiorenal syndrome (CRS) refers to the spectrum of disorders in which acute or chronic dysfunction of the heart or kidneys leads to acute or chronic dysfunction of the...\",\"metadata\":{\"categories\":[\"CRS\",\"cardio-renal syndrome\"],\"lastModified\":\"1761553996\",\"contentLength\":\"24460\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"17740\",\"recentViews\":\"17740\",\"dailyAvgViews\":591.3333129882812,\"qualityScore\":1,\"lastViewed\":\"1761882399\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761882399902,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Cardiorenal_syndrome\"],\"queryHash\":\"[\\\"page\\\",\\\"Cardiorenal_syndrome\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Cardiorenal syndrome\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Cardiorenal syndrome (CRS) refers to the spectrum of disorders in which acute or chronic dysfunction of the heart or kidneys leads to acute or chronic dysfunction of the other.[1] The condition is classified into five subtypes based on the primary organ dysfunction and whether the disease process is acute or chronic. The heart and the kidneys maintain hemodynamic stability and organ perfusion through an intricate network. CRS results from a complex interplay of hemodynamic alterations,...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"CRS, cardio-renal syndrome\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Cardiorenal_syndrome\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Cardiorenal syndrome\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Cardiorenal syndrome (CRS) refers to the spectrum of disorders in which acute or chronic dysfunction of the heart or kidneys leads to acute or chronic dysfunction of the other.[1] The condition is classified into five subtypes based on the primary organ dysfunction and whether the disease process is acute or chronic. The heart and the kidneys maintain hemodynamic stability and organ perfusion through an intricate network. CRS results from a complex interplay of hemodynamic alterations,...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Cardiorenal_syndrome\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Cardiorenal syndrome\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:13.996Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Cardiorenal syndrome\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Cardiorenal syndrome (CRS) refers to the spectrum of disorders in which acute or chronic dysfunction of the heart or kidneys leads to acute or chronic dysfunction of the other.[1] The condition is classified into five subtypes based on the primary organ dysfunction and whether the disease process is acute or chronic. The heart and the kidneys maintain hemodynamic stability and organ perfusion through an intricate network. CRS results from a complex interplay of hemodynamic alterations,...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZGFjZDNmNjEtYTBjNS00NThiLThkM2EtYzUzNjg5NWRjOTU4">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Cardiorenal_syndrome\"}]}]\n"])</script></body></html>